



**Center for Vaccine Ethics & Policy (CVEP)**  
**Vaccines and Global Health: The Week in Review**  
**31 January 2026 :: Issue 830**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS  
Editor and  
Executive Director Center for Vaccine Ethics & Policy  
[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).

***Support this knowledge-sharing service:*** Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.

***Contents [click to move among sections]***

- :: [Milestones, Perspectives](#)***
- :: [WHO](#)***
- :: [U.S. Immunization and Public Health Governance/Policy/Funding](#)***
- :: [Organization Announcements](#)***
- :: [Journal Watch](#)***
- :: [Pre-Print Servers](#)***
- :: [Think Tanks](#)***
- :: [Public Consultations/Call for Inputs/Call for Papers](#)***

## ***Milestones, Perspectives***

:::::::  
:::::::

### **In memoriam Dr William H. Foege (1936–2026)**


WHO 25 January 2026

*It is with great sadness that WHO learnt of the passing of Dr William Herbert Foege on 24 January 2026 at the age of 89 years.*

Dr William "Bill" H. Foege (1936–2026), an American physician and epidemiologist, was best known for devising the global strategy that led to the eradication of smallpox in the late 1970s. Born in Decorah, Iowa, he earned a BA from Pacific Lutheran University, completed his medical degree at the University of Washington in 1961, and later received his Master of Public Health from Harvard University in 1965.

Over the course of his distinguished career, Dr Foege served as Director of the United States Centers for Disease Control and Prevention from 1977 to 1983, where he played a central role in global immunization efforts and advanced several major public health investigations. He later co-founded the Task Force for Child Survival in 1984, contributed to The Carter Center's Health Programs and advised the Bill & Melinda Gates Foundation.

One of Dr Foege's most influential achievements was securing an unprecedented donation of ivermectin (Mectizan) from Merck & Co., Inc. to fight onchocerciasis (river blindness). In 1987, while serving as President and CEO of the Task Force for Global Health, Dr Foege was entrusted by Merck to manage this landmark donation. He oversaw the creation and early management of the Mectizan Donation Program – the first large-scale, disease-specific medicine donation programme in history and now one of the longest-running partnerships in global health. The Program has since distributed billions of ivermectin tablets across dozens of countries, transforming efforts to eliminate onchocerciasis and accelerating progress against lymphatic filariasis. Dr Foege's leadership was pivotal in establishing the collaborative model now considered standard practice for major neglected tropical disease programmes.



Dr Foege served as Executive Director of The Carter Center from 1986 to 1992, where he helped shape the institution's early vision and guided its global health strategy, including on Guinea-worm disease (dracunculiasis) eradication, river blindness, malaria and other neglected diseases.

In 2003, the Bill & Melinda Gates Foundation established the William H. Foege Global Fellowship Program, housed in the Rollins School of Public Health at Emory University, where Dr Foege was a

Presidential Distinguished Professor and supported a large number of mid-career professionals from developing countries.

A globally respected public health pioneer, honoured with the United States Presidential Medal of Freedom and numerous international accolades, Dr Foege's lifelong dedication to equity, scientific rigour and service to vulnerable communities continues to inspire generations of public health professionals.

In a post on X published on 25 January, Dr Tedros Adhanom Ghebreyesus, Director-General of WHO, stated that he was "saddened to learn of the passing of Dr William H. Foege, a preeminent public health expert whose leadership, prowess and commitment to collaboration helped protect the health of millions of people worldwide.

Dr Foege was instrumental to the global effort to eradicate the scourge of smallpox. His leadership within the US Centers for Disease Control and Prevention, and strong partnership and solidarity with WHO and health partners worldwide, helped advance and celebrate the life-saving benefits of vaccines. Above all, he was a champion for equity in health, and a visionary who recognized that investment in health is an investment in the futures of communities and countries."

:::::::

:::::::

## **WHO – 158th session of the Executive Board**

**2–7 February 2026**

*Live streaming from [this link](#)*

Main Documents [selected]

[EB158/1](#)

Provisional agenda

[EB158/1 \(annotated\)](#)

Provisional agenda (annotated)

[EB158/8](#)

Immunization Agenda 2030

Mid-term review

[EB158/23](#)

Poliomyelitis

[EB158/44](#)

### **Reform of the global health architecture and the UN80 initiative**

*[Scheduled for Friday agenda]*

1. This report provides an **overview of the context for reforming the global health architecture (GHA)1 and the UN80 Initiative; evolving proposals for GHA reform and the UN80 Initiative; the engagement of WHO in both the UN80 Initiative and GHA discussions**; their potential implications for WHO; and considerations for ensuring coherence across these initiatives to better advance the global health agenda.

2. **The significant contraction in official development assistance (ODA) since its 2022 peak, particularly in 2025,2 combined with escalating pressures on the traditional multilateral order have placed new strains on international organizations** both within and outside the United Nations system, countries, global health actors and the global health agenda. **These developments are putting at risk recent global health successes**, including: since 1990, the nearly 10-year gain in life expectancy globally, and the 60% and 40% reductions in under-5 and maternal mortality respectively; and, since 2000, the estimated 75 million, 25 million and 13 million

deaths averted due to vaccine-preventable diseases, HIV and malaria respectively. Additional achievements include the 2005 entry into force of both the WHO Framework Convention on Tobacco Control and the International Health Regulations (2005) and the adoption in 2025 of the WHO Pandemic Agreement...

**17. Optimizing the GHA [Global Health Architecture], and WHO's role in this new era, requires a common framework, in terms of the GHA's purpose, major functions, actors and capacities.** Such a framework could serve as a basis for guiding priorities, investment and enhanced collaboration modalities. **Developing such a framework requires engaging all key constituencies that comprise the GHA**, including countries, United Nations entities, global health initiatives, development banks, sovereign donors and philanthropies, product development partnerships, the private sector, civil society and academic institutions. As key actors and sponsors of the GHA, Member States have a central role in championing and helping to shape its reform.

18. To facilitate deliberations on the future of the GHA, and in the context of UN80, **WHO proposes to host an overarching, joint process that brings together current GHA reform discussions, and UN80 proposals with potential implications for global health, and complements them as needed with additional evidence gathering, research and consultation, to develop a common framework for the GHA.** Such a joint process would build on lessons learned from similar WHO-hosted inter-agency processes, such as the Access to COVID-19 Tools Accelerator (ACT-A) during the pandemic.

The process would be transparent, inclusive, and evidence based and generate common products that could be considered by all relevant entities. **Initiating such a process in the first half of 2026 would help to align with the timelines of the UN80 Initiative and time-bound consultations on GHA reform.** Member States would be further consulted on the design of the process, and thereafter kept informed on and engaged in the UN80 Initiative and the GHA consensus-building process through briefings and official updates, including through governing body processes as appropriate.

:::::::

:::::::

## Pandemic Preparedness

### [\*\*Pandemic preparedness slipping just as global risks grow, new 100 Days Mission report warns\*\*](#)

IPPS - International Pandemic Preparedness Secretariat

January 27, 2026

*Fifth Implementation Report highlights some progress, but warns that **fragile systems, uneven investment and pipeline stagnation threaten the world's ability to respond to another pandemic within 100 days***

*Key points:*

- :: The Fifth Implementation Report of the 100 Days Mission (100DM) finds that the 100-day target is not yet achievable in many areas, with **significant gaps persisting across diagnostics, therapeutics, vaccines and the systems required to deliver them rapidly and equitably.**
- :: The 100DM Scorecard 3.0 highlights continued pressure on global R&D pipelines, declining investment in pandemic countermeasures, and heavy reliance on a small number of funders.
- :: **Major reductions in global health and research budgets in 2025 have exposed structural vulnerabilities, disrupted development pipelines, and weakened preparedness.**
- :: A series of outbreaks in 2025, including mpox, H5N1, Ebola, Marburg, Rift Valley Fever, Chikungunya and measles, demonstrated persistent weaknesses in early detection, coordination and access.

:: **The report identifies 2026 as a decisive year as France begins its G7 presidency**, calling for coordinated action to operationalise therapeutics development, close diagnostics gaps, sustain vaccine investment, and secure the future of preparedness monitoring.

*The 100 Days Mission aims to ensure that safe, effective and affordable diagnostics, therapeutics and vaccines (DTVs) can be developed, approved and made available for scale-up within 100 days of a pandemic threat being identified. The Fifth Implementation Report assesses global progress toward this ambition during a year of major political, financial, and epidemiological change...*

.....  
.....

## **Vaccines: Trade; Customs**

### **[WCO announces updates to global customs codes to facilitate vaccination programmes and enhance preparedness for health emergencies](#)**

World Customs Organization 21 January 2026

:: Eighth edition of the 'universal language of trade', used for identifying and coding merchandise being traded internationally has been released.

**Two major changes come in the expanded identification of key vaccines and health emergency supplies stemming from lessons learned from the COVID-19 pandemic.**

:: Increased accuracy of trade data for purposes such as modelling and forecasting, supply chain management, price indices, and market identification are key benefits for governments.

The World Customs Organization has today published a major update of the Harmonized System – the international classification of goods that gives every traded product a standardized code. Managed by the WCO, the **HS is used by more than 200 countries and economies as a basis for their Customs tariffs and for the collection of international trade statistics**. The changes, which will come into effect on 1 January 2028, to allow time for national adaption, mark the conclusion of six years of technical work carried out by the WCO's 187 Members. These additions in the HS will provide visibility to products critical to health programmes and emergency response, enabling faster Customs clearance and ease of identification.

#### ***The HS facilitates visibility of trade in vaccines***

Vaccine production is today concentrated in a few countries, making trade a vital means for deploying vaccines globally. **The current classification of vaccines for human use in the HS provides insufficient granularity to assess international trade flows and easily implement trade policies for those vaccines**. Under the current HS 2022, vaccines are classified under just two subheadings for human and veterinary medicine. This lack of granularity is also often reflected in national tariff levels.

**HS 2028 introduces new headings (30.07 & 30.08) and subheadings for vaccines representing significant current or expected trade volumes and addresses priority diseases where immunization is vital.**

**The new structure reflects two dimensions: it distinguishes outbreak-prone diseases from endemic ones, and it aligns with WHO vaccination guidance by covering vaccines recommended for all programmes, for high-risk groups, for programmes with specific characteristics, and for diseases of local or sporadic nature.**

WCO Secretary General Ian Saunders, said: "This positive change to the Harmonized System allows for a greater understanding of vaccine availability and opens more opportunities for facilitated clearance of urgently required vaccines and medical equipment. It is a tangible contribution from Customs to global

development, the protection of society, and the ability of governments to respond effectively to future urgent demands. As these changes specifically cover vaccines against diseases that pose endemic or pandemic threats, they reflect recognition of the need to be prepared in advance for major risks as well as the positive role Customs can play in protecting the security and welfare of societies."

**By enhancing the visibility of these vaccines in the HS, the WCO aims to ensure consistent classification among trading parties and facilitate the implementation of preferential or faster treatment at borders, especially during emergencies.** The objective is also to provide policymakers with clearer and more reliable trade data to support the design and implementation of vaccination programmes and emergency plans.

**Vaccines for human medicine will be classified in heading 30.07, subdivided into 38 subheadings** (six-digit codes) and include vaccines against:

- Measles, rubella, varicella, shingles and mumps;
- Poliomyelitis, diphtheria, tetanus, pertussis, hepatitis, and Haemophilus influenzae type B;
- Tuberculosis, pneumococcal, rotavirus and human papillomavirus;
- Meningitis, typhoid, cholera, dengue, rabies and malaria;
- Influenza, respiratory syncytial virus (RSV) and coronaviruses; and,
- Yellow fever, smallpox, Mpox, Ebola, encephalitis, chikungunya and Streptococcus

Besides tuberculosis vaccines of the type Bacillus Calmette-Guérin (BCG), a subheading was created for "other tuberculosis vaccines" in anticipation of the production of tuberculosis vaccines for adolescents and adults which are currently under development, with some in advanced clinical trials. Furthermore, another subheading was created for "Streptococcus" vaccines to include another important pipeline vaccine approaching regulatory approval, that against Group B Streptococcus.

This is an exceptional case that the HS includes a good that this is not yet traded but this was considered crucial to enable to monitor whether an important vaccine reached the places it should reach and in the appropriate quantities.

**The WCO Harmonized System Committee and its Harmonized System Review Sub-Committee, worked closely with the World Health Organization (WHO) and the World Trade Organization (WTO) to understand how to best address the need for more clarity on vaccine flows within the structure of the HS and to ensure the changes were administrable at the border...**

.....  
.....  
.....

## **Polio – PHEIC**

**[Polio this week](#)** [28 January 2026]

*Headlines [Selected]*

**:: Alwaleed Philanthropies (Global) continues long-standing commitment to polio**

Three-year US\$15 million funding to support vaccination and surveillance activities in endemic and outbreak countries. [More](#).

### ***Summary of new polioviruses this week:***

- :: Afghanistan: one WPV1 case and five WPV1-positive environmental samples
- :: Pakistan: nine WPV1-positive environmental samples
- :: Algeria: one cVDPV2-positive environmental sample
- :: Central African Republic: one cVDPV2 case

- :: Chad: one cVDPV2 case and one cVDPV2-positive environmental sample
- :: Malawi: two cVDPV2-positive environmental samples
- :: Mali: one cVDPV2 case
- :: Namibia: one cVDPV2-positive environmental sample
- :: United Kingdom: one cVDPV2-positive environmental sample

:::::::

### ***Contents [click to move among sections]***

- :: [Milestones, Perspectives](#)
- :: [WHO](#)
- :: [U.S. Immunization and Public Health Governance/Policy/Funding](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)
- :: [Pre-Print Servers](#)
- :: [Think Tanks](#)
- :: [Public Consultations/Call for Inputs/Call for Papers](#)

:::::::

:::::::

### ***WHO & Regional Offices [01 Feb 2026]***

<https://www.who.int/news>

*Selected News/Announcements/Statements*

30 January 2026 *Departmental update*

[\*\*Testing the system: regional simulation exercises advance global health security\*\*](#)

30 January 2026 *Departmental update*

[\*\*Global regulatory authorities reaffirm labelling as a high-impact tool to combat antimicrobial resistance\*\*](#)

30 January 2026 *News release*

[\*\*Communities unite to address stigma and discrimination affecting people with neglected tropical diseases\*\*](#)

25 January 2026 *Departmental update*

[\*\*In memoriam Dr William H. Foege \(1936–2026\)\*\*](#)

### ***WHO Vaccines and Immunization [IVB]***

[https://www.who.int/health-topics/vaccines-and-immunization#tab=tab\\_1](https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1)

*News*

*No new digest content identified.*

### ***WHO Regional Offices***

*Selected Press Releases, Announcements*

[\*\*WHO African Region AFRO\*\*](#)

*No new digest content identified.*

### **WHO Region of the Americas PAHO**

:: 29 Jan 2026

### [\*\*Three months after Hurricane Melissa: PAHO continues supporting health system recovery across the Caribbean\*\*](#)

Washington, DC, 28 January 2026 (PAHO)- Ninety days after Hurricane Melissa swept across parts of the Caribbean, countries are transitioning from emergency response toward recovery—while continuing to confront public health risks linked to damaged infrastructure, disrupted services, and heightened vulnerability to disease. The Category 5...

### **WHO South-East Asia Region SEARO**

*No new digest content identified.*

### **WHO European Region EURO**

*No new digest content identified.*

### **WHO Eastern Mediterranean Region EMRO**

*No new digest content identified.*

### **WHO Western Pacific Region**

*No new digest content identified.*

::::::

### **WHO - Emergency situation reports**

*Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.*

### [\*\*Multi-country outbreak of cholera, epidemiological update #33 -27 January 2026\*\*](#)

#### *Overview*

From 1 January to 28 December 2025, a cumulative total of 614 828 cholera cases and 7598 deaths were reported from 33 countries across five WHO regions, with the Eastern Mediterranean Region recording the highest numbers, followed by the African Region, the South-East Asia Region, the Region of the Americas, and the Western Pacific Region. No cases were reported from the European Region during this period.

In December 2025 (epidemiological weeks 49 to 52) a total of 17 327 new cholera and acute watery diarrhoea (AWD) cases were reported from 16 countries across three WHO regions, showing a 25% decrease from November. In this period, 137 cholera-related deaths were reported globally, a 16% decrease from the previous month.

## **Multi-country outbreak of cholera**



**Epidemiological Update n. 33, published 27 January 2026<sup>1</sup>**

Cases – 614 828 Since Jan. 2025	Deaths – 7 598 Since Jan. 2025	Countries affected – 33 Since Jan. 2025	Population at risk 1 billion	Global risk – Very high
------------------------------------	-----------------------------------	--	---------------------------------	----------------------------

[OCV, vaccines, immunization not referenced in report]

::::::

### **Disease Outbreak News (DONs)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

### [\*\*30 January 2026 | Nipah virus infection - India\*\*](#)

## [\*\*26 January 2026 | Marburg virus disease - Ethiopia\*\*](#)

::::::

### **Weekly Epidemiological Record**

Vol. 101, No. 3, pp. 5-12 16 January 2026

<https://www.who.int/publications/journals/weekly-epidemiological-record>

:: Summary of the Global report on neglected tropical diseases 2025

[Reviewed earlier]

::::::

### **New WHO Publications**

<https://www.who.int/publications>

*Selected*

30 January 2026

[\*\*Scaling innovations in public health systems: guidance and toolkit\*\*](#)

29 January 2026

[\*\*Middle East respiratory syndrome: global summary and assessment of risk\*\*](#)

28 January 2026

[\*\*Regional consultation to develop a Practical Guide on Immunization Waste Management, 8–9 December 2025\*\*](#)

26 January 2026

[\*\*State of systems for drinking-water, sanitation and hygiene: global update 2025\*\*](#)

::::::

::::::

::::::

### **Africa**

**Africa CDC** [01 Feb 2026]

<https://africacdc.org/>

*Press Releases, Statements [Selected]*

[\*\*Africa CDC Establishes Central Data Repository to Strengthen Public Health Surveillance\*\*](#)

Addis Ababa, 27 January 2026 – A new Central Data Repository (CDR) launched by the Africa Centres for Disease Control and Prevention (Africa CDC) aims to strengthen how public health data is integrated, analysed and used across the continent at a time of growing and increasingly complex health risks.

While improvements have been made in outbreak detection and reporting, public health data in Africa remains fragmented and dispersed across multiple systems that are often not interoperable. This limits the ability of countries and regional institutions to rapidly synthesise information, identify emerging risks and translate data into timely and coordinated public health action.

The CDR addresses this challenge by providing a secure and interoperable platform that integrates surveillance, laboratory and programme data from national and regional systems. The platform enhances Africa CDC's ability to track health threats, support advanced analysis and forecasting as well as coordinate responses across borders, including through the One Health approach...

Press Releases

**[Ethiopia Ends Marburg Outbreak, Showcasing Rapid Action and Health System Strength](#)**

26 January 2026

:::::

:::::

**China – CDC+**

**National Health Commission of the People's Republic of China** [01 Feb 2026]

<http://en.nhc.gov.cn/>

News

*No new digest content identified.*

**National Medical Products Administration – PRC** [01 Feb 2026]

<http://english.nmpa.gov.cn/>

News

**[China revises drug administration regulations to spur innovation, tighten oversight](#)**

Xinhua / Updated: 2026-01-28

BEIJING -- China has revised regulations concerning drug administration in a bid to promote drug innovation, strengthen management of online sales of medicines and reinforce drug safety supervision.

The modified regulations for implementing the Drug Administration Law, which Chinese Premier Li Qiang has signed a State Council decree to promulgate, comprise nine chapters and 89 articles and are set to take effect on May 15, an official statement said on Tuesday.

At the core of this revision effort is the drug research and registration system. The revised regulations emphasize a clinical value-oriented approach to drug development, encouraging innovation and supporting the clinical application and use of new medicines.

The document refines requirements for the management of clinical trials and introduces accelerated review pathways for drug marketing authorization. Clearer procedures are also provided for drug re-registration and for switching between prescription and over-the-counter medicines...

**China CDC**

**[CCDC Weekly Reports: Current Volume \(7\)](#)**

**2026-01-30 / No. 5 NEGLECTED TROPICAL DISEASE ISSUE**

[PDF of this issue](#)

:: [Preplanned Studies: Epidemiological Transition and Spatial Expansion of Mountain-Type Zoonotic Visceral Leishmaniasis — China, 2010–2024](#)

:: [Preplanned Studies: Effectiveness of an Integrated One Health Intervention on Schistosoma japonicum Infection in Wild Rodents — Anhui Province, China, 2022–2024](#)

:: [Preplanned Studies: Knowledge, Attitudes, and Practices of Dog Owners Toward a Smart Health Education Pillbox for Controlling Echinococcosis — Western China, 2023–2024](#)

:: [Preplanned Studies: Attitudes as a Critical Mediator Between Schistosomiasis Knowledge and Practices Among Students, with Implications for Behavior Change Interventions — Pemba Island, Zanzibar, Tanzania, 2024](#)

:: [Outbreak Reports: First Imported Case of Cerebral Schistosomiasis Mansoni — China, May 2025](#)

:::::

:::::

**Europe**

## **European Centre for Disease Prevention and Control**

<https://www.ecdc.europa.eu/en>

*News/Updates/Reports/Publications [Selected]*

### **[Joint ECDC and Africa CDC training to strengthen surveillance and epidemic intelligence in Sierra Leone](#)**

30 Jan 2026

### **[ECDC and WHO/Europe renew joint commitment to strengthen European health security and collaboration on public health](#)**

29 Jan 2026

#### *Surveillance and monitoring*

### **[Communicable disease threats report, 24-30 January 2026, week 5](#)**

30 Jan 2026

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 24-30 January 2026 and includes updates on respiratory virus epidemiology in the EU/EEA, Marburg virus disease, cholera, avian influenza, bacillus in infant formula, and nipah virus disease.

## **European Medicines Agency [EMA]**

<https://www.ema.europa.eu/en/news>

*News & Press Releases*

### **[Meeting highlights from the Committee for Medicinal Products for Human Use \(CHMP\) 26-29 January 2026](#)**

Six new medicines recommended for approval; another nine medicines recommended for extension of their therapeutic indications

30 January 2026

:::::::

:::::::

## **India**

### **[National Centre for Disease Control](#)**

*Directorate General of Health Services, Ministry of Health & Family Welfare*

*Announcements*

*No new digest content identified.*

:::::::

:::::::

:::::::

## **U.S. Immunization and Public Health Governance/Policy/Funding**

*Given the continuing extraordinary situation in the U.S., we have established a separate section of the digest to capture and organize key content. Please note that we will selectively include external analysis and comment, either boxing or indenting this content under the relevant organization/action. We recognize that despite the volume of content in this section, this summary is indicative and not exhaustive*

## **Executive Branch - White House, State, HHS, FDA, CDC+**

### **White House**

*Presidential Actions – Executive Orders; Memoranda; Proclamations*

*No new digest content identified.*

**Department of State**

Press Releases - Selected

Joint Statement

**Joint Statement of the United States and African Union on the Launch of a Strategic Investment Working Group**

January 28, 2026

... In this regard, the Government of the United States and the AUC have agreed to the establishment of a U.S.-AUC Strategic Infrastructure and Investment Working Group (SIWG), to promote and advance U.S.-Africa economic partnerships that create jobs, prosperity, and economic security both in America and across Africa...

**HHS**

Press Room - Selected

**Secretary Kennedy Appoints New Interagency Autism Coordinating Committee to Advance Fight Against Autism**

WASHINGTON — JANUARY 28, 2026 — The U.S. Department of Health and Human Services (HHS) today announced the appointment of 21 new members to the Interagency Autism Coordinating Committee (IACC). These appointments reflect the commitment of Secretary Robert F. Kennedy, Jr. to support breakthrough innovations in autism research, diagnosis, treatment, and prevention by bringing the nation's understanding of and policies concerning autism into alignment with gold-standard science.

"President Trump directed us to bring autism research into the 21st century," Secretary Kennedy said. "We are doing that by appointing the most qualified experts—leaders with decades of experience studying, researching, and treating autism. These public servants will pursue rigorous science and deliver the answers Americans deserve."...

**NIH [to 01 Feb 2026]**

<http://www.nih.gov/>

News Releases

*No new digest content identified.*

**FDA**

Press Announcements

FDA News Releases

*No new digest content identified.*

**FDA CBER**

What's New for Biologics

*No new digest content identified.*

**FDA VRBPAC [Vaccines and Related Biological Products Advisory Committee]**

Advisory Committee Calendar

***No future meetings posted.***

**FDA Pediatric Advisory Committee Meeting**

Advisory Committee Calendar

***No future meetings posted.***

**CDC**

<http://www.cdc.gov/media/index.html>

Latest News - Selected

*No new digest content identified.*

**CDC – Immunization Safety Office (ISO)**

<https://www.cdc.gov/vaccine-safety-systems/about/cdc-monitoring-program.html>

*No new digest content identified.*

**ACIP**

**2026 Meetings Schedule** *[no agenda content posted]*

- February 25-26
- June 24-25
- October 21-22

**Leading Public Health Groups Seek Expedited Injunctive Relief Against Immunization Schedule Changes, Upcoming ACIP Meeting; Hearing Scheduled Friday, February 13**

January 13, 2026

A group of medical professional societies, led by the American Academy of Pediatrics (AAP) and including the American Public Health Association (APHA), seek to enjoin the upcoming February 25-26 ACIP meeting and vacate recent changes to the pediatric immunization schedule. A hearing on plaintiffs' preliminary injunction is scheduled for Friday, February 13.

**National Vaccine Program Committee (NVAC)**

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

**No 2025 meeting dates posted.**

**Advisory Commission on Childhood Vaccines (ACCV)**

<https://www.hrsa.gov/advisory-committees/vaccines/meetings>

*No new digest content identified.*

**MMWR Weekly**

<https://www.cdc.gov/mmwr/index2025.html>

*No new digest content identified.*

:::::::

**NSF**

News

*No new digest content identified.*

:::::::

**U.S. Congress**

**House of Representatives**

*No new digest content identified.*

**U.S. Senate**

**Senate Health, Education, Labor, and Pensions (HELP) Committee**

*No new digest content identified.*

:::::::

**Supreme Court, Federal & Appellate Courts**

O'Neill Institute – Health Care Litigation Tracker [Georgetown University]

<https://litigationtracker.law.georgetown.edu/>

*No new digest content identified.*

\*\*\*\*\*

\*\*\*\*\*

\*\*\*\*\*

## **U.S. Medical Societies, Health Organizations**

*This inventory is evolving and may not capture all instances of relevant comment and analysis.*

### **American Academy of Family Physicians (AAFP)**

<https://www.aafp.org/news/media-center.html>

(Accessed 01 Feb 2026)

*No new digest content identified.*

### **American Academy of Pediatrics (AAP)**

<https://www.aap.org/en/news-room/news-releases-from-the-aap/>

(Accessed 01 Feb 2026)

*News*

#### **American Academy of Pediatrics Issues Recommended Childhood and Adolescent Immunization Schedule for 2026**

January 26, 2026

The American Academy of Pediatrics has published the “Recommended Childhood and Adolescent Immunization Schedule: United States, 2026,” that continues to recommend routine immunization for protection against 18 diseases, including RSV, hepatitis A, hepatitis B, rotavirus, influenza, and meningococcal disease.

### **American College of Physicians (ACP)**

<https://www.acponline.org/more-acp-news>

(Accessed 01 Feb 2026)

*News Releases*

#### **Nearly half of CDC surveillance databases have halted updates, raising concerns about health data gaps**

01/30/26

*Annals of Internal Medicine*

*Abstract*

Real-time federal surveillance of diseases and health care delivery informs clinical guidance and public health policy. However, in 2025, some U.S. Centers for Disease Control and Prevention (CDC) databases seemed to have “unexplained pauses” and ceased or delayed updates. The CDC public data catalog was audited to identify paused databases that had previously been updated at least monthly and evaluated their characteristics. Of 1359 catalog records examined on 28 October 2025, eighty-two were previously updated at least monthly. On the basis of each database’s stated periodicity, allowing for an additional 30-day grace period, their status was classified as either current or paused as of 28 October 2025. Forty-four databases (54%) were current, and 38 (46%) were paused. Thirty-four of the 38 databases (89%) had no data entries dated within 6 months of the date of analysis, whereas 4 (11%) paused more recently. Of the 38 paused databases, 33 (87%) were vaccination-related topics compared with none of the 44 current databases. Of the 5 paused databases on other topics, 4 addressed respiratory diseases, including disease burden and nonvaccine prevention measures,

whereas 1 addressed public health (drug overdose deaths). The persistence of pauses as of 2 December 2025 was examined. Only 1 of the 38 paused databases had been updated. Such long pauses may have compromised evidence for decision making and policies by clinicians, administrators, professional organizations, and policymakers. Federal databases should adopt minimum transparency standards, including displaying the current update status, with a rationale if paused, and next expected update with criteria for resumption. Without such standards, unexplained pauses in surveillance risk undermining evidence-based medicine and public trust.

### **ACP continues to advocate against changes to vaccine recommendations**

01/30/26

ACP Advocate

### **America's Health Insurance Plans (AHIP)**

<https://www.ahip.org/news>

(Accessed 01 Feb 2026)

*News*

*No new digest content identified.*

### **American Geriatrics Society (AGS)**

<https://www.americangeriatrics.org/media-center>

(Accessed 01 Feb 2026)

*Recent Press Releases*

*No new digest content identified.*

### **American Medical Association (AMA)**

<https://www.ama-assn.org/press-center>

(Accessed 01 Feb 2026)

*Press Releases*

*No new digest content identified.*

### **American Osteopathic Association (AOA)**

<https://osteopathic.org/news/>

(Accessed 01 Feb 2026)

*Latest News*

*No new digest content identified.*

### **American Public Health Association (APHA)**

<https://www.apha.org/news-and-media/news-releases?sortFieldName=ItemDate&sortDisplayName>Newest&sortMode=desc>

(Accessed 01 Feb 2026)

*No new digest content identified.*

### **Infectious Diseases Society of America (IDSA)**

<https://www.idsociety.org/>

(Accessed 01 Feb 2026)

*News releases and statements*

*No new digest content identified.*

### **National Foundation for Infectious Diseases (NFID)**

<https://www.nfid.org/news-updates/>

(Accessed 01 Feb 2026)

*News and Updates*

January 26, 2026

#### **NFID Statement on AAP Childhood Immunization Schedule**

The National Foundation for Infectious Diseases (NFID) strongly endorses the American Academy of Pediatrics' (AAP) childhood immunization schedule and affirms AAP's evidence-based recommendations to protect children from vaccine-preventable diseases. Clear, consistent, and science-based guidance is essential to help families make well-informed decisions about their children's health. NFID urges policymakers and clinicians to uphold transparent, data-driven immunization policies grounded in U.S. epidemiology and rigorous expert review so children can receive the full protection recommended by trusted pediatricians and public health experts.

January 23, 2026

#### **2025 NFID Impact Report: Breaking Through the Noise**

In 2025, the National Foundation for Infectious Diseases (NFID) remained a steadfast voice for science and evidence-based guidance. As we look back on 2025, the numbers tell a story of resilience, innovation, and support.

### **National Medical Association (NMA)**

<https://nmanet.org/blog/>

(Accessed 01 Feb 2026)

*Latest News*

#### **National Medical Association Endorses AAP 2026 Childhood Immunization Schedule**

January 26, 2026

The physician members and leaders of the National Medical Association (NMA) continue to recommend an evidence-based immunization schedule that protects against 18 diseases and have endorsed the 2026 childhood immunization schedule released today by the American Academy of Pediatrics (AAP). The AAP schedule is thoroughly researched and rooted in science and differs significantly from recent changes to the Centers for Disease Control and Prevention's (CDC) federal immunization schedule, which have created unnecessary and harmful confusion about routine childhood vaccinations.

The NMA encourages health care providers, families, and caregivers to rely on the AAP schedule and continue vaccinating children to protect them and their communities from preventable diseases.

### **Pediatric Infectious Diseases Society (PIDS)**

<https://pids.org/news-announcements/>

(Accessed 01 Feb 2026)

*News & Announcements*

Jan. 26, 2026

#### **PIDS Supports AAP Childhood and Adolescent Immunization Schedule for 2026**

The Pediatric Infectious Diseases Society is one of a dozen medical and healthcare organizations to formally endorse the American Academy of Pediatrics' Recommended Childhood and Adolescent Immunization Schedule for 2026....

## **Society for Healthcare Epidemiology of America (SHEA)**

<https://shea-online.org/news/>

(Accessed 01 Feb 2026)

*No new digest content identified.*

## **Society for Maternal-Fetal Medicine (SMFM)**

<https://www.smfm.org/>

(Accessed 01 Feb 2026)

*News*

*No new digest content identified.*

:::::::

:::::::

## **Civil Society – Individuals, Organizations, Institutions *[Selected]***

:::::::

### **Kaiser Family Foundation/KFF [01 Feb 2026]**

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

#### **[Global COVID-19 Tracker](#)**

*Issue Brief Jan 30, 2026*

This tracker provides data on global COVID-19 cases and deaths by country, region, and income-level. Additionally, the tracker reports current closure, economic, and health system policy responses to the COVID-19 pandemic globally. This tracker will be updated as new data are available.

#### **[Vaccinations](#)**

Jan 30, 2026

*State vaccine policies, child, flu, and pneumonia vaccination data.*

Numerous actions by the federal and state governments in recent years have made changes to vaccine policies, including the set of recommended vaccines for children and adults and school vaccination requirements. This collection provides the latest state-specific data on vaccine requirements for school attendance, requirements for private insurance coverage of vaccines, child vaccination and exemption rates, and flu and pneumonia vaccination rates.

#### **[State Requirements for Private Insurance Coverage of Vaccines](#)**

Jan 29, 2026 Data

#### **[Overview of President Trump's Executive Actions on Global Health](#)**

*Fact Sheet Jan 27, 2026*

This guide provides an overview of executive orders and other executive actions made by the Trump Administration since January 21, 2025 that directly address or affect U.S. global health efforts. This resource identifies each executive action, describes its purpose and actions taken, and outlines the implications and what happens next for each. The resource will be updated as needed.

:::::::

#### **Vaccine Integrity Project – CIDRAP [to 01 Feb 2026]**

<https://www.cidrap.umn.edu/vaccine-integrity-project>

*Announcements*

*No new digest content identified.*

:::::::

### **Paul Offit, MD – *Beyond the Noise***

Substack: <https://pauloffit.substack.com/>  
[Selected]

#### **RFK Jr.'s Strategy for Restoring Trust**

*Just make one false claim after the next and never look back. Never admit you were wrong. Never apologize.*

Jan 20, 2026

:::::::

### **Art Caplan, PhD, NYU**

*Perspectives*

*No new digest content identified.*

:::::::

## **Int Organizations/Institutions**

### **Institut Pasteur**

<https://www.pasteur.fr/en/press-area>

#### **Institut Pasteur statement on U.S. administration's attacks against biomedical research, global public health action and vaccination**

*Press release 28.01.2026*

For several months now, the current U.S. administration has consistently attacked and endeavored to weaken biomedical research and public health action in the United States and worldwide with unparalleled vigor. This situation has many consequences – both ethical and economic – but above all it is a grave attack on healthcare protection, and an unprecedented assault on the systems and institutions responsible for protecting lives.

Certain key scientific topics in infectious diseases, immunology, vaccinology and women's health have been deprioritized as research projects eligible for federal funding. In addition, the United States has abruptly withdrawn from major global public health programs, dismantling the U.S. Agency for International Development (USAID) and just recently moving ahead with its decision to exit the World Health Organization (WHO). The general scale of the threats now facing these activities is huge, and the implications for public health are likely to be considerable. According to *The Lancet* <sup>[1]</sup>, the end of USAID could result in the loss of 14.1 million lives by 2030, including 4.5 million children under the age of 5. This is not only a grave injustice for the populations directly affected, but it demonstrates a broader lack of understanding of how populations are nowadays interconnected, where lack of disease control in certain affected areas can easily result in previously controlled or new infections spreading across the globe.

In the same vein, the U.S. administration has undertaken an overhaul of its vaccine policy, radically challenging the scientific consensus in this major public health field and jeopardizing the health of millions of people, often including children, in the United States and beyond. Vaccines are among the safest and most effective public health interventions. Globally, around half of the decline in child mortality can be attributed to vaccination. As a result of 50 years of vaccination, a child born today has a 40% increased chance of survival for every year of infancy and childhood.<sup>[2]</sup>

Due to political pressure, certain U.S. government agencies, whose very mission is to protect the public's health, publish messages that are not backed with scientific data. As of November 19, 2025, the website of the Centers for Disease Control and Prevention (CDC), the primary U.S. federal agency for public health protection, states that "the claim "vaccines do not cause autism" is not an evidence-

based claim because studies have not ruled out the possibility that infant vaccines cause autism". This confusing statement is factually incorrect. The Institut Pasteur wishes to clarify and reaffirm that reproducible and validated scientific studies have found no evidence of a link between infant vaccination and autism. On the contrary, they conclude that vaccines are not associated with autism [3][4]. The cause of autism is still an open and active research field, although serious scientific studies, including some conducted at the Institut Pasteur, have now identified genetic causes in many people with autism [5]. The CDC's statement thus contradicts the scientific consensus, which was reached by widely recognized experts following decades of rigorous scientific analysis, thereby sowing the seeds of doubt and perpetuating disinformation.

As of January 5, 2026, the U.S. authorities are no longer recommending universal immunization of children with essential vaccines, including those against hepatitis A, hepatitis B, meningococcal disease, influenza and rotavirus. This decision contradicts the conclusions of most public health studies conducted on this topic. It deprives very young children of crucial protection against these potentially severe diseases for their own and their family's health. In the case of hepatitis A, universal two-dose programs have reported efficacy of 95% or more between 3 and 5 years after administration [6], and it is acknowledged that the recommendations of the American Advisory Committee on Immunization Practices (ACIP) for universal immunization of children aged 12 to 23 months against hepatitis A led to a 95.5% reduction in hepatitis A cases between 1996 and 2011 in the United States [7]. Studies conducted in the Western Pacific region have shown that vaccination against hepatitis B prevented 37 million cases of chronic infection in children born between 1990 and 2014, thereby averting 7 million deaths in this population [8]. Lastly, meningococcal vaccines are still the most effective strategy for preventing invasive meningococcal infections, which are extremely serious diseases that within hours may be fatal or cause lifelong complications. The risk of invasive meningococcal infections cannot be considered negligible in the United States, with the emergence and spread of meningococcal strains with growing resistance to first-line antibiotics, and the resurgence in invasive bacterial infections following the COVID-19 pandemic. Lower vaccination coverage in the United States could increase vulnerability to imported strains and, conversely, facilitate the export of cases to other countries. These developments have been documented recently, particularly in connection with travel to the Middle East. These concerns are further amplified by the fact that the United States is soon to co-host the FIFA World Cup, a mass gathering event [9].

The latest series of decisions by the U.S. administration is extremely dangerous for at least three reasons. First, it misleads the public. By spreading false information and disregarding decades of progress in public health, the U.S. administration may discourage many parents from having their children vaccinated, even though this is a public health measure that has saved hundreds of millions of lives. Second, it signals the pre-eminence of ideological considerations over scientific consensus, in disregard for human life and health. Last, by creating confusion between established scientific facts and unfounded, mostly individual, opinions, the U.S. administration's rhetoric would have us believe that a consensus of the international scientific community, based on rigorous and confirmed studies, carries the same weight as an unfounded opinion. By implying that the arduous process put in place to validate scientific data, based on cross-validation, methodological rigor and critical examination, has the same value as an anecdote, this situation contributes to the destruction of the intellectual and ethical milestones underpinning the very principles of progress, human protection and our democracies.

Against this backdrop of increasing attacks on scientific truth and public health, the Institut Pasteur reaffirms its determination to combat all forms of disinformation by pursuing its scientific research, reiterating established facts and demonstrating the virtues of rationality.

:::::  
:::::

**Contents [click to move among sections]**

:: [Milestones, Perspectives](#)

:: WHO  
:: Organization Announcements  
:: Journal Watch  
:: Pre-Print Servers

:::::  
:::::

### ***Organization Announcements***

**Paul G. Allen Frontiers Group** [01 Feb 2026]

<https://alleninstitute.org/news-press/>

*News*

*No new digest content identified.*

**BMGF - Gates Foundation** [01 Feb 2026]

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases & Statements*

*No new digest content identified.*

**CARB-X** [01 Feb 2026]

<https://carb-x.org/>

*News*

01.28.2026 |

**[Wellcome renews AMR innovation partnership with CARB-X with US\\$60M award](#)**

CARB-X announced today its renewed partnership with Wellcome, a global charitable foundation which co-founded CARB-X in 2016. Between 2026 and 2028, Wellcome will provide CARB-X with new funding of up to US\$60 million to support early-stage research and development of innovative antibacterial products to protect lives from bacterial infections globally.

**Chan Zuckerberg Initiative** [01 Feb 2026]

<https://chanzuckerberg.com/newsroom/>

*Newsroom*

*No new digest content identified.*

**CEPI – Coalition for Epidemic Preparedness Innovations** [01 Feb 2026]

<http://cepi.net/>

*CEPI News, Blog*

*No new digest content identified.*

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 01 Feb 2026]

<https://cioms.ch/>

*News; Publications; Events*

**[Working Group XV – Pharmacoepidemiology for Public Health - PUBLIC CONSULTATION DRAFT REPORT](#)**

Pharmacoepidemiology aims to appraise and understand the use and effects — both beneficial and adverse — of medicines in real-world settings. As such it can be considered a bridge science, linking clinical pharmacology, epidemiology, public health and the social sciences. Deadline to submit your comments is 13 March 2026.

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [01 Feb 2026]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

**DNDI – Drugs for Neglected Diseases initiative** [01 Feb 2026]

<https://dndi.org/press/press-releases/>

*Press Releases*

*No new digest content identified.*

**Duke Global Health Innovation Center** [01 Feb 2026]

<https://dukeghic.org/>

*News*

*No new digest content identified.*

**EDCTP** [01 Feb 2026]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*News*

*No new digest content identified.*

**Emory Vaccine Center** [01 Feb 2026]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [01 Feb 2026]

<http://www.euvaccine.eu/>

*News*

*No new digest content identified.*

**Fondation Merieux** [01 Feb 2026]

<http://www.fondation-merieux.org/>

*Actualités*

*No new digest content identified.*

**Gates Medical Research Institute** [01 Feb 2026]

<https://www.gatesmri.org/news>

*The Gates Medical Research Institute is a non-profit organization dedicated to the discovery, development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited.*

*News: Articles and Publications*

**[Discovery and development of a new oxazolidinone with reduced toxicity for the treatment of tuberculosis](#)**

January 13, 2026•Nature Medicine

**Gavi** [to 01 Feb 2026]

<https://www.gavi.org/>

*News Releases*

*No new digest content identified.*

**GE2P2 Global Foundation** [01 Feb 2026]

[www.ge2p2.org](http://www.ge2p2.org)

*News/Analysis/Publications-Digests/Statements/Digests*

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – May 2025](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 12 Nov 2025](#)

:: [Genomics, Gene Editing, Convergent Biosciences: Governance, Ethics, Policy, Practice – A Monthly Review – Nov 2025](#)

**GHIT Fund** [01 Feb 2026]

<https://www.ghitfund.org/newsroom/press>

*Press Releases*

*No new digest content identified.*

**Global Fund** [to 01 Feb 2026]

<https://www.theglobalfund.org/en/news/>

*News Releases*

28 January 2026

**[Saudi Arabia Pledges US\\$39 Million to the Global Fund's Eighth Replenishment, Reinforcing Global Health Leadership](#)**

The Kingdom of Saudi Arabia, through the Saudi Fund for Development (SFD), has pledged S\$39 million to the Eighth Replenishment of the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund), reaffirming its long-standing commitment to...

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [01 Feb

2026]

<https://www.glopид-r.org/>

*News & Events*

*No new digest content identified.*

**Hilleman Laboratories** [01 Feb 2026]

<http://www.hilleman-labs.org/>

*News & Insights*

*No new digest content identified.*

**HHMI - Howard Hughes Medical Institute** [01 Feb 2026]

<https://www.hhmi.org/news>

*Press Room*

*No new digest content identified.*

**Human Immunome Project** [nee Human Vaccines Project] [01 Feb 2026]

<https://www.humanimmunomeproject.org/>

*News*

*No new digest content identified.*

**IAVI** [01 Feb 2026]

<https://www.iavi.org/>

*Press Releases, Features*

*Features*

**[IAVI and Partners Announce the 8th Global Forum on TB Vaccines in April 2027 in Zaragoza, Spain](#)**

January 23, 2026

The 8th Global Forum will take place from April 12-14, 2027—marking a return to the European region and the first time in a Spanish-speaking country

[Read more](#)

**INSERM** [01 Feb 2026]

<https://www.inserm.fr/en/home/>

*Press Releases*

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**[ICH \[International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use\]](#)** [to 01 Feb 2026]

<https://www.ich.org/>

*News/Pubs/Press Releases [Selected]*

Ongoing Public Consultations

^

> [Q3E EWG Guideline for Extractables and Leachables](#)

> [E22 EWG General Considerations for Patient Preference Studies](#)

<https://www.ich.org/page/public-consultations>

**ICRC** [to 01 Feb 2026]

<https://www.icrc.org/en/news>

*Latest press releases and statements*

**ICRC president: States must harness momentum to improve Gaza's dire humanitarian situation in next phase of ceasefire**

Statement

29-01-2026

**Israel and the occupied territories: Release and transfer operations under ceasefire agreement completed**

News release

29-01-2026

**ICRC President: Respect for international humanitarian law preserves pathways back to peace**

Statement

29-01-2026

**ICRC President Urges Renewed Commitment to Laws of War at Westminster**

Article

30-01-2026

**IFFIm** [01 Feb 2026]

<http://www.iffim.org/>

*Press Releases/Announcements*

**IFRC** [to 01 Feb 2026]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press releases*

*No new digest content identified.*

**IPPS - International Pandemic Preparedness Secretariat** [01 Feb 2026]

<https://ippsecretariat.org/news/>

*News*

**Pandemic preparedness slipping just as global risks grow, new 100 Days Mission report warns**

January 27, 2026

**Institut Pasteur** [01 Feb 2026]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*Press release 28.01.2026*

**Institut Pasteur statement on U.S. administration's attacks against biomedical research, global public health action and vaccination**

**ISC / International Science Council** [to 01 Feb 2026]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*No new digest content identified.*

**International Union of Immunological Societies (IUIS)**

<https://iuis.org/>

*News, Resources*

*No new digest content identified.*

**IVAC** [01 Feb 2026]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*

**IVI** [01 Feb 2026]

<http://www.ivi.int/>

*IVI News & Announcements*

*No new digest content identified.*

**Johns Hopkins Center for Health Security** [01 Feb 2026]

<https://centerforhealthsecurity.org/newsroom>

*Center News [Selected]*

*No new digest content identified.*

**Robert Wood Johnson Foundation** [to 01 Feb 2026]

<https://www.rwjf.org/en/about-rwjf/newsroom.html>

*Latest News and Highlights*

*No new digest content identified.*

**MSF/ Médecins Sans Frontières** [to 01 Feb 2026]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Gaza-Israel war*

[\*\*Addressing frequently asked questions and allegations about MSF's work in Gaza\*\*](#)

Project Update 30 Jan 2026

*Gaza-Israel war*

[\*\*MSF statement on sharing staff information and humanitarian operations in Palestine\*\*](#)

Statement 30 Jan 2026

*South Sudan*

[\*\*South Sudan government blocks opposition-held areas from humanitarian access\*\*](#)

Press Release 30 Jan 2026

**National Academy of Medicine** - USA [to 01 Feb 2026]

<https://nam.edu/programs/>

*News, Stories, Insights*

*No new digest content identified.*

**National Academies-Sciences-Engineering-Medicine [NASEM]**- USA [to 01 Feb 2026]

<https://www.nationalacademies.org/newsroom>

*News*

**[Sustaining a Vibrant and Secure U.S. Research Enterprise](#)**

*Announcement*

In an increasingly competitive international environment, the United States is facing new challenges to its leadership in science and technology (S&T) . Our resource brings together the National Academies' substantial body of work related to advancing U.S. S&T leadership while protecting the U.S. enterprise from foreign misappropriation of scientific and technological information.

Jan 28, 2026

**[National Institutes of Health Need Agencywide Strategy to Prioritize and Fund Pediatric Research, Says New Report](#)**

*News Release*

Childhood health is foundational to lifelong well-being. A new National Academies report makes recommendations on how NIH and Congress can best support pediatric health research and improve health outcomes through childhood and beyond.

Jan 28, 2026

**[NAS Awards 2026 Public Welfare Medal to Francis Collins](#)**

*Announcement*

The National Academy of Sciences will present its prestigious Public Welfare Medal to Francis S. Collins, former director of the National Institutes of Health, for his pioneering research in human genetics and critical contributions to public welfare as the leader of the Human Genome Project.

Jan 27, 2026

**PATH** [01 Feb 2026]

<https://www.path.org/media-center/>

*Newsroom [Selected]*

*No new digest content identified.*

**Sabin Vaccine Institute** [01 Feb 2026]

<https://www.sabin.org/press/>

*Latest News & Press Releases*

*No new digest content identified.*

**UNAIDS** [01 Feb 2026]

<http://www.unaids.org/en>

*News, Stories, Updates*

*No new digest content identified.*

**UNICEF** [to 01 Feb 2026]

<https://www.unicef.org/media/press-releases>

*Latest press releases, news notes and statements [Selected]*

*Remarks* 30 January 2026

**Darfur's children living on a thin line between abandonment and hope**

GENEVA/PORT SUDAN, 30 January 2026, – "In Darfur today, reaching a single child can take days of negotiation, security clearances, and travel across sand roads under shifting frontlines. But the work is critical, particularly in places like Tawila – from where I have just returned - where hundreds of thousands...

**Unitaid** [01 Feb 2026]

<https://unitaid.org/>

*News releases*

**Unitaid to intensify cervical cancer elimination efforts with latest funding opportunity**

26 January 2026

**Vaccine Equity Cooperative [nee Initiative]** [01 Feb 2026]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccine Confidence Project** [01 Feb 2026]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children's Hospital of Philadelphia** [01 Feb 2026]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

**Vaccine Update Newsletter January 2026**

**Wellcome Trust** [01 Feb 2026]

<https://wellcome.org/news/all>

*News, Opinion, Reports*

*No new digest content identified.*

**The Wistar Institute** [to 01 Feb 2026]

<https://www.wistar.org/news/press-releases>

*Press Releases*

January 29, 2026

**Wistar Scientists Discover How Gut-Derived Metabolite Acts as Immune "Volume Knob" Via Macrophages**

Research reveals molecule acts as an immune-system amplifier, boosting the body's inflammatory defenses during early infection but elevating them to deadly levels when infections progress to sepsis.

January 26, 2026

## **The Wistar Institute Announces Dr. Dario Altieri Leadership Transition**

Board of Trustees conducting president & CEO search process

*Dario C. Altieri, M.D., Wistar's president and CEO, director of the Ellen and Ronald Caplan Cancer Center, and Robert and Penny Fox Distinguished Professor, will step down from his leadership role effective December 2026. In the interim, the Board of Trustees will undertake a comprehensive national search process to identify his successor.*

**World Bank** [to 01 Feb 2026]

<http://www.worldbank.org/en/news/all>

*News [Selected]*

### **Strengthening Health Systems in Sahel's Fragile Communities**

Results Highlights Between 2018 and 2024, results achieved included: Expanded and improved health services: Over 5 million people in Mali and Mauritania accessed basic...  
Date: January 26, 2026 Type: Result Brief

**WFPHA: World Federation of Public Health Associations** [01 Feb 2026]

<https://www.wfpha.org/>

*Blog, Events*

*No new digest announcements identified.*

**World Medical Association [WMA]** [to 06 Sep 025]

<https://www.wma.net/news-press/press-releases/>

*Press Releases*

### **World Physicians Urge Iran to End Violence Against Health Personnel**

28.01.2026

**World Organisation for Animal Health [OIE]** [01 Feb 2026]

<https://www.oie.int/>

*Press Releases, Statements*

*No new digest announcements identified.*

:::::

:::::

**ARM [Alliance for Regenerative Medicine]** [01 Feb 2026]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

*No new digest announcements identified.*

**BIO** [01 Feb 2026]

<https://www.bio.org/press-releases>

*Press Releases*

*No new digest announcements identified.*

**DCVMN – Developing Country Vaccine Manufacturers Network** [01 Feb 2026]

<http://www.dcvmn.org/>

*News; Upcoming events*  
*No new digest announcements identified.*

**ICBA – International Council of Biotechnology Associations** [01 Feb 2026]

<https://internationalbiotech.org/>

*News*

*No new digest announcements identified.*

**IFPMA** [01 Feb 2026]

<https://ifpma.org/>

*News & Resources*

*Website not responding at inquiry.*

**International Alliance of Patients' Organizations – IAPO** [01 Feb 2026]

<https://www.iapo.org.uk/news>

*Press and media [Selected]*

*No new digest announcements identified.*

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

*No new digest announcements identified.*

**PhRMA** [01 Feb 2026]

<http://www.phrma.org/>

*Press Releases*

*No new digest announcements identified.*

::::::

::::::

**Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements**

*We recognize that this listing is indicative but certainly not exhaustive. We invite nomination of other vaccine developers for potential addition to those monitored below.*

**AstraZeneca**

*Press Releases*

**[AstraZeneca plans to invest \\$15 billion in China through 2030 to pioneer the next-generation of innovative medicines](#)**

PUBLISHED 29 January 2026

*Landmark investment will expand AstraZeneca's capabilities to discover, develop, and manufacture transformative new treatments in China*

**Bavarian Nordic**

*Latest News* - *No new digest announcements identified.*

**BioCubaFarma – Cuba**

Últimas Noticias - No new digest announcements identified.

**Biological E**

News - No new digest announcements identified.

**BioNTech**

Press Releases

28 January 2026

[\*\*BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer\*\*](#)

**Boehringer**

Press Releases - No new digest announcements identified.

**CanSinoBIO**

News - Website not responding at inquiry.

**CIGB**

Latest News - No new digest announcements identified.

**CinnaGen**

Recent News - No new digest announcements identified.

**Clover Biopharmaceuticals – China**

News - No new digest announcements identified.

**CSL Sequirus**

News Releases - No new digest announcements identified.

**Curevac**

News - Website now directs to BioNTech site

**Daiichi Sankyo**

Press Releases - No new digest announcements identified.

**Gamaleya National Center/Sputnik**

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

**GSK**

Press releases for media

[\*\*GSK's RSV vaccine, Arexvy, receives European approval for expanded use in all adults 18 years and older\*\*](#)

GSK plc (LSE/NYSE: GSK) today announced that its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy, has been approved by the European Commission\* (EC) for use in adults aged 18 years and older. Arexvy was the first RSV vaccine authorised in the European Economic Area for the prevention of lower respiratory tract disease (LRTD) caused by RSV. It was previously approved in adults aged 60 years and above, as well as in those aged 50 to 59 years who are at increased risk for RSV disease. Today's updated indication now enables European countries to make the vaccine available to all adults aged 18 years and older...

**EuBiologics, S Korea**

News - No new digest announcements identified.

**HIPRA**

Press releases - No new digest announcements identified.

**IMBCAMS**, China

Home - Website not responding at inquiry.

**JNJ Innovative Medicine [Janssen]**

Press Releases - No new digest announcements identified.

**Merck**

News releases - No new digest announcements identified.

**Nanogen**

News - No new digest announcements identified.

**Novartis**

News - No new digest announcements identified.

**Novavax**

Press Releases - No new digest announcements identified.

**Pfizer**

Recent Press Releases - No new digest announcements identified.

**R-Pharm**

<https://rpharm-us.com/index.php>

[No news or media page identified]

**Sanofi Pasteur**

Press Releases - No new digest announcements identified.

**Serum Institute**

News & Announcements - No new digest announcements identified.

**Sinopharm/WIBPBIBP**

News - No new digest announcements identified.

**Sinovac**

Press Releases - No new digest announcements identified.

**SK Biosciences**

Press Releases

**[SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family](#)**

2026.01.29

:: Global phase 1/2 clinical trial initiated for GBP511, a vaccine targeting the Sarbecovirus Family

:: Next-generation vaccine leveraging SKYcovione's recombinant protein-based platform and nanoparticle technology

:: SK bioscience will continue to strengthen a Mid- to Long-Term global vaccine strategy centered on universal vaccines for future pandemic preparedness

**Takeda**

Newsroom - No new digest announcements identified.

**Valneva**

Press Releases - No new digest announcements identified.

**WestVac Biopharma**

Media - No new digest announcements identified.

**Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

::::::

::::::

**Contents [click to move among sections]**

:: Milestones, Perspectives

:: WHO

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

::::::

::::::

**Journal Watch**

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

**AJOB Empirical Bioethics**

Volume 16, 2025 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

**AMA Journal of Ethics**

Volume 27, Number 12: E823-875 December 2025

<https://journalofethics.ama-assn.org/issue/electronic-health-record-evolution>

**Aging Is Bad for You?**

At some point along life's trajectory, growing becomes aging. Gerotherapeutics—biologically-based approaches to health that target processes of aging—seem poised to respond. This theme issue investigates ethical valences of what gerotherapeutics suggest about our socially, culturally, and historically entrenched patterns of pathologizing and medicalizing aging. Advancement in our understanding of physiological mechanisms of aging has prompted some to reconceive lifespans as

health spans. Geroscience also suggests the need to critically evaluate whether and to what extent we should think of anti-aging ventures as legitimate enterprises of health care. Normative roles played by aging in our personal and relational narratives, in our expectations about how duration and quality of life confer value to life, and in how life extension promotes or undermines our notions of wisdom and a good life are all at stake.

**American Journal of Human Genetics**

Jan 08, 2026 Volume 113 Issue 1 p1-234

<https://www.cell.com/ajhg/current>

[Reviewed earlier]

**American Journal of Infection Control**

December 2025 Volume 53 Issue 12 p1243-1366

<http://www.ajicjournal.org/current>

[Reviewed earlier]

**American Journal of Preventive Medicine**

February 2026 Volume 70 Issue 2

<https://www.ajpmonline.org/current>

[Reviewed earlier]

**American Journal of Public Health**

January 2026 116(1)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

**American Journal of Tropical Medicine and Hygiene**

Volume 113 (2025): Issue 6 (Dec 2025)

<https://www.ajtmh.org/view/journals/tpmd/113/3/tpmd.113.issue-6.xml>

[Reviewed earlier]

**Annals of Internal Medicine**

January 2026 Volume 179, Issue 1

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

**Artificial Intelligence – An International Journal**

Volume 349 December 2025

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/349/suppl/C>

[Reviewed earlier]

**BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 01 Feb 2026)

[No new digest content identified]

### **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 01 Feb 2026)

[No new digest content identified]

### **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 01 Feb 2026)

#### **The measles vaccine's effectiveness during an epidemic: a test negative case control study (Tunisia, 2019)**

Cyrine Bennasrallah, Amani Maatouk, Manel Ben Fredj

Research Open access 28 January 2026

### **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 01 Feb 2026)

[No new digest content identified]

### **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 01 Feb 2026)

[No new digest content identified]

### **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 01 Feb 2026)

[No new digest content identified]

### **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 01 Feb 2026)

*Articles*

#### **Exploring barriers to and motivations for vaccine uptake in a typhoid vaccine trial in Vellore, South India: a qualitative study**

Nimi Elizabeth Thomas, B. L. Thabitha Malini, Jacob John

Research Open access 31 January 2026

#### **Promoting awareness of childhood vaccines in the Uyghur Türk community in Türkiye: a health education intervention**

Nimetcan Mehmet Orhun, Mehmet Enes Gökler, Salih Mollahaliloğlu

Research Open access 30 January 2026

#### **Analysis of the characteristics of parents' reasons for refusing HPV vaccination for their daughters: a cross-sectional study**

Yihan Hu, Xianglong Li, Ping Zhou  
Research Open access 30 January 2026

**Factors influencing vaccine refusal in children: an umbrella review on COVID-19 and childhood vaccinations**

Saadet Güzel, Hasret Yalçınöz Baysal, Engin Kurşun  
Systematic Review Open access 28 January 2026

**BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>  
(Accessed 01 Feb 2026)  
[No new digest content identified]

**BMJ Evidence-Based Medicine**

December 2025 - Volume 30 - 6  
<https://ebm.bmj.com/content/30/6>  
[Reviewed earlier]

**BMJ Global Health**

January 2026 - Volume 11 - 1  
<https://gh.bmj.com/content/11/1>  
[Reviewed earlier]

**Bulletin of the Atomic Scientists**

DIGITAL MAGAZINE - December 2025  
<https://thebulletin.org/magazine/2025-12/#post-heading>  
[Reviewed earlier]

**Bulletin of the World Health Organization**

Volume 104, Number 1, January 2026, 1-60  
[Reviewed earlier]

**Cell**

Jan 22, 2026 Volume 189 Issue 2 p343-696  
<https://www.cell.com/cell/current>  
[Reviewed earlier]

**Cell and Gene Therapy Insights**

May 2025 Issue Volume 11 Issue 4  
<https://www.insights.bio/cell-and-gene-therapy-insights/journal/250/volume-11-issue-4>  
[Reviewed earlier]

**Child Care, Health and Development**

Volume 52, Issue 1 January 2026

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

### **Clinical Pharmacology & Therapeutics**

Volume 119, Issue 2 Pages: 281-563 February 2026

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[New edition; No digest content identified]

### **Clinical Therapeutics**

January 2026 Volume 48 Issue 1 p1-134

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

### **Clinical Trials**

Volume 22 Issue 6, December 2025

<https://journals.sagepub.com/toc/ctja/22/6>

[Reviewed earlier]

### **Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 01 Feb 2026]

[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 159 December 2025

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/159/suppl/C>

[Reviewed earlier]

### **The CRISPR Journal**

Volume 8, Issue 6 / December 2025

<https://www.liebertpub.com/toc/crispr/8/6>

[Reviewed earlier]

### **Current Genetic Medicine Reports**

Volume 13, Issue 1 December 2025

<https://link.springer.com/journal/40142/volumes-and-issues/13-1>

[Reviewed earlier]

### **Current Medical Research and Opinion**

Volume 41, Issue 3 2025

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

**Current Opinion in Infectious Diseases**

October 2025 - Volume 38 - Issue 5

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

*PAEDIATRIC AND NEONATAL INFECTIONS*

[Reviewed earlier]

**Current Protocols in Human Genetics**

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 01 Feb 2026]

[No new digest content identified]

**Cytotherapy**

March 2026 Volume 28 Issue 3

<https://www.isct-cytotherapy.org/current>

[Reviewed earlier]

**Developing World Bioethics**

Volume 25, Issue 4 Pages: 253-323 December 2025

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

**Development in Practice**

Volume 35, Issue 5, 2025

<https://www.tandfonline.com/toc/cdip20/35/5?nav=tocList>

[Reviewed earlier]

**Development Policy Review**

Volume 44, Issue 1 January 2026

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

**Disaster Medicine and Public Health Preparedness**

Volume 19 - 2025

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

**Disasters**

Volume 50, Issue 1 January 2026

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

**eBioMedicine**

Volume 122 December 2025

<https://www.sciencedirect.com/journal/ebiomedicine/vol/121/suppl/C>  
[Reviewed earlier]

### **EMBO Reports**

Volume 27, Issue 1 January 2026  
<https://www.embopress.org/toc/14693178/current>  
[Reviewed earlier]

### **Emerging Infectious Diseases**

Volume 31, Number 11—November 2025  
<http://wwwnc.cdc.gov/eid/>  
[Reviewed earlier]

### **Epidemics**

Volume 53 December 2025  
<https://www.sciencedirect.com/journal/epidemics/vol/53/suppl/C>  
[Reviewed earlier]

### **Epidemiology and Infection**

Volume 153 - 2025  
<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>  
[Reviewed earlier]

### **Ethics & Human Research**

Volume 48, Issue 1 Pages: 1-48 January–February 2026  
<https://onlinelibrary.wiley.com/toc/25782363/current>  
***Research and pregnant women • Considerations for informed consent***  
[Reviewed earlier]

### **Ethics & International Affairs**

Volume 39 - Issue 3 - Fall 2025  
<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue> [

[Reviewed earlier]

### **Ethics, Medicine and Public Health**

Volume 33 2025  
<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>  
[Reviewed earlier]

### **The European Journal of Public Health**

Volume 35, Issue 6, December 2025  
<https://academic.oup.com/eurpub/issue/35/6>  
[Reviewed earlier]

**Expert Review of Vaccines**

Volume 25, 2026 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

**Foreign Affairs**

January/February 2026 Volume 105, Number 1

<https://www.foreignaffairs.com/issues/2026/105/1>

[Reviewed earlier]

**Forum for Development Studies**

Volume 52, 2025 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

***The Rebirth of the Global South: Geopolitics, Imageries, and Developmental Realities***

[Reviewed earlier]

**Frontiers in Genetics**

<https://www.frontiersin.org/journals/genetics>

[Accessed 01 Feb 2026]

*Opinion*

**[Imagining an ethics for Synthetic Biology](#)**

Varsha Aravind Paleri, Kristien Hens

Accepted on 29 Jan 2026

**Frontiers in Genome Editing**

<https://www.frontiersin.org/journals/genome-editing>

[Accessed 01 Feb 2026]

[No new digest content identified]

**Frontiers in Medicine**

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463>

[Accessed 01 Feb 2026]

[No new digest content identified]

**Gene Therapy – Nature**

Volume 32 Issue 6, December 2025

<https://www.nature.com/gt/volumes/32/issues/6>

[Reviewed earlier]

**Genetics in Medicines**

Volume 28, Issue 1 January 2026

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/28/issue/1>

*Research article Open access*

**[Toward ethical provenance tracking: The GA4GH model data access agreement \(DAA\)](#)**

Alexander Bernier, Bartha Maria Knoppers, Jonathan Lawson, Robyn McDougall, ... Vasiliki Rahimzadeh  
Article 101594

*Research article Open access*

**Ten years of exome sequencing and reanalysis among racial, ethnic, and ancestral groups: The importance of equitable reanalysis access**

Andrew Giles, Kimberly Zayhowski, Maggie Ruderman, John Ranola, ... Meghan Towne  
Article 101576

**Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 01 Feb 2026]

[No new digest content identified]

**Global Health Action**

Volume 18, Issue 1 (2025)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

**Global Health: Science and Practice (GHSP)**

December 2025 | Volume 13 | Number 2

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

**Global Legal Monitor & Legal Reports – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>

[https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date\\_desc](https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc)

[Accessed 01 Feb 2026]

[No new digest content identified]

**Global Public Health**

Volume 20, Issue 1 (2025)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

**Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 01 Feb 2026]

[No new digest content identified]

**Health and Human Rights**

Volume 27, Issue 2, December 2025

<https://www.hhrjournal.org/volume-27-issue-2-december-2025/>

[Reviewed earlier]

**Health Economics, Policy and Law**

Volume 20 - Issue 4 - October 2025

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

**Health Policy and Planning**

Volume 40, Issue 10, November 2025

<https://academic.oup.com/heapol/issue/40/10>

[Reviewed earlier]

**Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 01 Feb 2026]

[No new digest content identified]

**Human Gene Therapy**

Volume 36, Issue 23-24 / December 2025

[https://www.liebertpub.com/toc/hum/36/2\\_3-24](https://www.liebertpub.com/toc/hum/36/2_3-24)

[Reviewed earlier]

**Humanitarian Practice Network**

<https://odihpn.org/>

[Accessed 01 Feb 2026]

[No new digest content identified]

**Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 21 Issue 1, 2025

<https://www.tandfonline.com/toc/khvi20/21/1?nav=tocList>

*Selected Content*

[Reviewed earlier]

**Immunity**

Jan 13, 2026 Volume 59 Issue 1 p1-228

<https://www.cell.com/immunity/current>

[Reviewed earlier]

**Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>

[Accessed 01 Feb 2026]

[No new digest content identified]

**Infectious Diseases of Poverty**

[http://www.idpjournal.com/content\]](http://www.idpjournal.com/content)

[Accessed 01 Feb 2026]

**[Confronting neglected tropical diseases: a moral and strategic imperative for global equity](#)**

Dirk Engels, Xiao-Nong Zhou

Editorial Open access 29 January 2026 Article: 17

**International Health**

Volume 17, Issue 6, November 2025

<https://academic.oup.com/inthealth/issue/17/6>

[Reviewed earlier]

**International Human Rights Law Review**

Volume 14 (2025): Issue 1 (Jun 2025)

<https://brill.com/view/journals/hrlr/14/1/hrlr.14.issue-1.xml>

[Reviewed earlier]

**International Journal of Community Medicine and Public Health**

Vol. 12 No. 12 (2025): December 2025

<https://www.ijcmph.com/index.php/ijcmph/issue/view/131>

[Reviewed earlier]

**International Journal of Epidemiology**

Volume 54, Issue 5, October 2025

<https://academic.oup.com/ije/issue/54/5>

[Reviewed earlier]

**International Journal of Human Rights in Healthcare**

Volume 18, Issue 5 4 November 2025

<https://www.emerald.com/ijhrh/issue/18/5>

[Reviewed earlier]

**JAMA**

January 27, 2026, Vol 335, No. 4, Pages 291-378

<https://jamanetwork.com/journals/jama/currentissue>

*Perspective*

**[Influenza A\(H3N2\) Subclade K Virus Threat and Response](#)**

Maria Zambon, BSc, BM, BCh, PhD; Frederick G. Hayden, MD

*JAMA*. 2026;335(4):307-310. doi:10.1001/jama.2025.25903

This Perspective examines the currently circulating influenza A(H3N2) subclade K virus, including antigenic variants, vaccine effectiveness, and countermeasures.

**JAMA Health Forum**

January 2026, Vol 7, No. 1

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

**JAMA Pediatrics**

January 2026, Vol 180, No. 1, Pages 3-120

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

**JBI Evidence Synthesis**

January 2026 - Volume 24 - Issue 1

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

**Journal of Adolescent Health**

February 2026 Volume 78 Issue 2 p203-370

<https://www.jahonline.org/current>

[Reviewed earlier]

**Journal of Artificial Intelligence Research**

Vol. 83 (2025)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

**Journal of Bioethical Inquiry**

Volume 22, Issue 3 September 2025

<https://link.springer.com/journal/11673/volumes-and-issues/22-3>

[Reviewed earlier]

**Journal of Community Health**

Volume 50, Issue 6 December 2025

<https://link.springer.com/journal/10900/volumes-and-issues/50-6>

[Reviewed earlier]

**Journal of Current Medical Research and Opinion**

*...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.*

Vol. 8 No. 01 (2025)

<https://www.cmro.in/index.php/jcmro/issue/view/91>

[Reviewed earlier]

**Journal of Development Economics**

Volume 178 January 2026

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/178/suppl/C>

[Reviewed earlier]

**Journal of Empirical Research on Human Research Ethics**

Volume 20 Issue 5, December 2025

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

**Journal of Epidemiology & Community Health**

November 2025 - Volume 79 - 11

<https://jech.bmjjournals.org/content/79/11>

[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 18, Issue 4 December 2025

<https://onlinelibrary.wiley.com/toc/17565391/current>

[New issue; No digest content identified]

**Journal of Global Ethics**

Volume 21, Issue 2 (2025)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 36, Number 4, November 2025

<https://muse.jhu.edu/issue/55986>

*Table of Contents*

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 27, Issue 5 October 2025

<https://link.springer.com/journal/10903/volumes-and-issues/27-5>

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 23, Issue 4 (2025)

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

**Journal of International Development**

Volume 38, Issue 1 Pages: 1-191 January 2026

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

**Journal of Law, Medicine & Ethics**

Volume 53 - Issue 3 - Fall 2025

<https://www.cambridge.org/core/journals/journal-of-law-medicine-and-ethics/latest-issue>

**Public Health, Markets, and Law**

[Reviewed earlier]

**Journal of Medical Ethics**

December 2025 - Volume 51 - 12

<http://jme.bmj.com/content/current>

[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 12, Issue 3 (2025)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

**The Journal of Pediatrics**

Volume 288 January 2026

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/288/suppl/C>

[New issue; No digest content identified]

**Journal of Pharmaceutical Policy and Practice**

Volume 18, 2025 Issue 1

<https://www.tandfonline.com/toc/jppp20/18/1?nav=tocList>

[Reviewed earlier]

**Journal of Public Health Management & Practice**

November/December 2025 - Volume 31 - Issue 6

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

**Journal of Public Health Policy**

Volume 46, Issue 4 December 2025

<https://link.springer.com/journal/41271/volumes-and-issues/46-4>

[Reviewed earlier]

**Journal of the Royal Society – Interface**

Volume 22, Issue 233 1 December 2025

<https://royalsocietypublishing.org/toc/rsif/current>

*Life Sciences–Mathematics interface*

[\*\*Integrating deep-learning methods and web-based data sources for surveillance, forecasting and early warning of avian influenza\*\*](#) *Open Access*

Zahra Movahedi Nia; Nicola Bragazzi; Itlala Gizo; Murray Gillies; Emma Gardner; Doris Leung; Jude Dzevela Kong

**Journal of Travel Medicine**

Volume 32, Issue 8, December 2025  
<https://academic.oup.com/jtm/issue>  
[Reviewed earlier]

## **The Lancet**

Jan 24, 2026 Volume 407 Number 10526 p309-468  
<https://www.thelancet.com/journals/lancet/issue/current>

*Comment*

### **[Yellow fever vaccine minimum fractional dosing does not extend to infants](#)**

Lance Turtle

*Articles*

### **[Low-dose yellow fever vaccination in infants: a randomised, double-blind, non-inferiority trial](#)**

Derick Kimathi, et al.

*Summary*

**Background**

WHO recommends fractional dose vaccination to address yellow fever vaccine shortages during outbreaks. In adults, a 500 IU dose has recently been shown to be non-inferior to the full standard dose, but the minimum effective dose for children is unknown.

**Methods**

We conducted a randomised, double-blind, non-inferiority trial at two centres in Kenya and Uganda, including infants aged 9–12 months with no previous yellow fever vaccination or infection. Participants were randomly assigned 1:1 in blocks of variable sizes of four, six, or eight to receive either the standard dose (>13 000 IU) or 500 IU of the Institut Pasteur de Dakar (Dakar, Senegal) 17D-204 yellow fever vaccine, co-administered with the measles–rubella vaccine. The primary outcome was seroconversion 28 days post-vaccination, defined as a four-fold or greater increase in antibody titre at day 28 from baseline (day 0), as measured by the 50% plaque reduction neutralisation test. Non-inferiority was shown if the lower bound of the 95% CI for the difference in seroconversion rates between doses exceeded –10 percentage points. Safety was assessed in the safety population, which included all participants who received a study vaccine dose. This study is registered with [ClinicalTrials.gov \(NCT04059471\)](#) and is complete.

**Findings**

Between Oct 7, 2021, and June 14, 2023, 420 infants were enrolled and randomly assigned (210 participants in each group). The seroconversion rate at day 28 was 99% (95% CI 96–100; 177 of 179 infants) for the standard dose and 93% (88–96; 166 of 179 infants) for the 500 IU dose in the per-protocol population. The difference in seroconversion rate was –6·15 percentage points (95% CI –10·27 to –2·02); therefore, non-inferiority was not met for the 500 IU dose. 12 serious adverse events were reported in the study (eight in the 500 IU dose group and four in the standard dose group), but all were considered unrelated to vaccination.

**Interpretation**

Compared with the standard yellow fever vaccine dose, a dose of 500 IU did not meet the non-inferiority criterion, suggesting that minimum dose requirements in adults are not generalisable to infants. Therefore, standard yellow fever doses should be used for infants in the routine WHO Expanded Programme on Immunization.

**Funding**

European and Developing Countries Clinical Trials Partnership and the Wellcome Trust.

## **The Lancet Child & Adolescent Health**

Dec 2025 Volume 9 Number 12 p817-890, e24-e27

<https://www.thelancet.com/journals/lanchi/issue/current>  
[Reviewed earlier]

### **Lancet Digital Health**

Dec 2025 Volume 7 Number 12

<https://www.thelancet.com/journals/landig/issue/current>

*Editorial*

#### **[Preserving the integrity of clinical trials](#)**

The Lancet Digital Health

### **Lancet Global Health**

Dec 2025 Volume 13 Number 12 e1991-e2179

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

### **Lancet Infectious Diseases**

Feb 2026 Volume 26 Number 2 p111-212, e77-e131

<https://www.thelancet.com/journals/laninf/issue/current>

*Articles*

#### **[Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era \(RECOVER-EHR\): a retrospective cohort study](#)**

Bingyu Zhang, et al on behalf of the RECOVER Consortium

**[Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial](#)**  
Kirsten E Lyke, et al.

**[Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium \(MPX-COHORT and POQS-FU-PLUS\): a 24-month prospective and retrospective cohort study](#)**

Christophe Van Dijck, et al.

*Personal View*

#### **[A transformation in cholera surveillance](#)**

Amanda K Debes, Erin T Baumgartner, Kendra N Williams, David A Sack

### **Lancet Public Health**

Dec 2025 Volume 10 Number 12 e1006-e1085

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

### **Lancet Respiratory Medicine**

Dec 2025 Volume 13 Number 12 p1041-1118, e59-e63

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

**Maternal and Child Health Journal**

Volume 29, Issue 10 October 2025

<https://link.springer.com/journal/10995/volumes-and-issues/29-10>

[Reviewed earlier]

**Medical Decision Making (MDM)**

Volume 46 Issue 1, January 2026

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

**The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 103, Issue S1 Pages: 1-462 November 2025

<https://onlinelibrary.wiley.com/toc/14680009/current>

***Special Issue: Mental Health and Substance Use Challenges Facing the United States:  
What Can State Policy Makers Do***

[New issue; No digest content identified]

**Molecular Therapy**

Jan 07, 2026 Volume 34 Issue 1 p1-644

<https://www.cell.com/molecular-therapy/current>

[Reviewed earlier]

**Nature**

Volume 649 Issue 8099, 29 January 2026

<https://www.nature.com/nature/volumes/649/issues/8099>

Editorial 28 Jan 2026

**Wikipedia is needed now more than ever, 25 years on**

The online encyclopedia is an antidote to an increasingly poisoned information ecosystem.  
Researchers should help to nourish it.

**Nature Biotechnology**

Volume 43 Issue 12, December 2025

<https://www.nature.com/nbt/volumes/43/issues/12>

[Reviewed earlier]

**Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 01 Feb 2026)

[Reviewed earlier]

**Nature Genetics**

Volume 57 Issue 12, December 2025

<https://www.nature.com/ng/volumes/57/issues/12>

[Reviewed earlier]

## **Nature Human Behaviour**

Volume 9 Issue 10, October 2025

<https://www.nature.com/nathumbehav/volumes/9/issues/10>

Article 10 Sept 2025

### **Interventions to reduce vaccine hesitancy among adolescents: a cluster-randomized trial**

In this randomized controlled trial, Baudouin et al. find that both pedagogical activities and a chatbot improve ninth graders' attitudes and knowledge about vaccination, offering scalable ways to counter vaccine hesitancy in adolescents.

N. Baudouin, S. de Rouilhan, H. Mercier

## **Nature Medicine**

Volume 31 Issue 12, December 2025

<https://www.nature.com/nm/volumes/31/issues/12>

[Reviewed earlier]

## **Nature Reviews Drug Discovery**

Volume 24 Issue 12, December 2025

<https://www.nature.com/nrd/volumes/24/issues/12>

[Reviewed earlier]

## **Nature Reviews Genetics**

Volume 26 Issue 12, December 2025

<https://www.nature.com/nrg/volumes/26/issues/12>

[Reviewed earlier]

## **Nature Reviews Immunology**

Volume 25 Issue 12, December 2025

<https://www.nature.com/nri/volumes/25/issues/12>

[Reviewed earlier]

## **New England Journal of Medicine Volume**

Volume 394 No. 5 January 29, 2026

<https://www.nejm.org/toc/nejm/medical-journal>

*Perspective*

### **The Essential Role of States in Protecting Immunization Access**

M. Cohen and Others

In the face of U.S. federal policy shifts that threaten to destabilize vaccine access and weaken clinical guidance, states can step in and protect their residents.

## **NEJM Evidence**

Volume 4 No. 12 December 2025

<https://evidence.nejm.org/toc/evid/current>

*NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.*

[Reviewed earlier]

## **njp Vaccines**

<https://www.nature.com/npjvaccines/>

[Accessed 01 Feb 2026]

[No new digest content identified]

## **Pediatrics**

Volume 156, Issue 6 December 2025

<https://publications.aap.org/pediatrics/issue/156/6>

[Reviewed earlier]

## **PharmacoEconomics**

Volume 43, Issue 12 December 2025

<https://link.springer.com/journal/40273/volumes-and-issues/43-12>

[Reviewed earlier]

## **PLoS Biology**

<https://journals.plos.org/plosbiology/>

(Accessed 01 Feb 2026)

[No new digest content identified]

## **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 01 Feb 2026)

[No new digest content identified]

## **PLoS Global Public Health**

[https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\\_NEWEST\\_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60](https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60)

(Accessed 01 Feb 2026)

### **[Human papillomavirus \(HPV\) vaccine uptake and its associated factors among adolescent girls in Kathmandu District, Nepal: A cross-sectional study](#)**

Shristi Thapa, Priyanka Timsina, Bandana Paneru, Archana Pokhrel, Archana Shrestha

Research Article | published 30 Jan 2026 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0005893>

### **[Insights on the implementation strategies for a potential new tuberculosis vaccine in South Africa](#)**

Katherine A. Thomas, Choice Okoro, Thobani Ntshiqwa, Verena Damovsky, Deanne Goldberg, Omphile Ramokhoase, Rebecca A. Clark, Waasila Jassat, Gavin J. Churchyard, Fareed Abdullah, Mmamapudi Kubjane, Janet Seeley, Salome Charalambous, Richard G. White

Research Article | published 30 Jan 2026 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0005047>

## **PLoS Medicine**

<https://journals.plos.org/plosmedicine/>

(Accessed 01 Feb 2026)

[No new digest content identified]

### **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 01 Feb 2026)

### **[Effect of the time of day for vaccination on the immune response to Ebola Virus Disease vaccines: A modeling study from PREVAC randomized trial](#)**

Ange-Marie D. Kpetigo, Marie Alexandre, Aboubacar Camara, Abdoul Beavogui, Seydou Doumbia, Mark Kieh, Bailah Leigh, Samba Sow, Linda Wittkop, Anne-Ayglane Soutthiphong, Irina Maljkovic Berry, Suzanne Fleck, Pauline Akoo, Benjamin Hamze, Deborah Watson-Jones, Jens H. Kuhn, Brian Greenwood, Laura Richert, Yazdan Yazdanpanah, Yves Lévy, Rodolphe Thiébaut, Mélanie Prague, PREVAC Study Team, Edouard Lhomme

Research Article | published 30 Jan 2026 PLOS Neglected Tropical Diseases

<https://doi.org/10.1371/journal.pntd.0013950>

### **PLoS One**

<http://www.plosone.org/>

[Accessed 01 Feb 2026]

[No new digest content identified]

### **PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 01 Feb 2026]

[No new digest content identified]

### **PNAS - Proceedings of the National Academy of Sciences of the United States**

January 27, 2026 vol. 123 no. 4

<https://www.pnas.org/toc/pnas/123/4>

[New issue; No digest content identified]

### **PNAS Nexus**

Volume 4, Issue 11, November 2025

<https://academic.oup.com/pnasnexus/issue/4/11>

[Reviewed earlier]

### **Prehospital & Disaster Medicine**

Volume 40 - Issue 6 - December 2025

<https://www.cambridge.org/core/journalsprehospital-and-disaster-medicine/latest-issue>

[New issue; No digest content identified]

### **Preventive Medicine**

Volume 203 February 2026

<https://www.sciencedirect.com/journal/preventive-medicine/vol/203/suppl/C>

[New issue; No digest content identified]

**Proceedings of the Royal Society B**

Volume 293, Issue 2063 January 2026

<https://royalsocietypublishing.org/toc/rspb/current>

*Evidence synthesis*

**[Infectious disease outbreak controllability: biological, social and public health factors](#)**

Robin N. Thompson, et al.

**Public Health**

Volume 249 December 2025

<https://www.sciencedirect.com/journal/public-health/vol/249/suppl/C>

[Reviewed earlier]

**Public Health Ethics**

Volume 18, Issue 2, July 2025

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

**Public Health Genomics**

2025, Vol. 28, No. 1

<https://karger.com/phg/issue/28/1>

[Reviewed earlier]

**Public Health Reports**

Volume 140 Issue 5-6, Sep-Oct/Nov-Dec 2025

<https://journals.sagepub.com/toc/phrg/140/5-6>

[Reviewed earlier]

**Qualitative Health Research**

Volume 36 Issue 1, January 2026

<https://journals.sagepub.com/toc/QHR/current>

[New issue; No digest content identified]

**Research Ethics**

Volume 22 Issue 1, January 2026

<http://journals.sagepub.com/toc/reab/current>

[New issue; No digest content identified]

**Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 01 Feb 2026]

[No new digest content identified]

**Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Latest Articles*

[No new digest content identified]

**Risk Analysis**

Volume 46, Issue 1 January 2026

<https://onlinelibrary.wiley.com/toc/15396924/current>

[New issue; No digest content identified]

**Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 01 Feb 2026]

[No new digest content identified]

**Royal Society Open Science**

Volume 12, Issue 12 1 December 2025

<https://royalsocietypublishing.org/toc/rsos/current>

[Reviewed earlier]

**Science**

Volume 391| Issue 6784| 29 Jan 2026

<https://www.science.org/toc/science/current>

*Editorial*

**[China turns the tables in biotech](#)**

BY H. Holden Thorp

29 Jan 2026

**Science and Engineering Ethics**

Volume 31, Issue 6 December 2025

<https://link.springer.com/journal/11948/volumes-and-issues/31-6>

[Reviewed earlier]

**Science Translational Medicine**

Volume 18| Issue 834| 28 Jan 2026

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

**Scientific Reports**

<https://www.nature.com/srep/articles?type=article>

[Accessed 01 Feb 2026]

[No new digest content identified]

## **Social Science & Medicine**

Volume 386 December 2025

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/386/suppl/C>

[Reviewed earlier]

## **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 01 Feb 2026]

[No new digest content identified]

## **Theoretical Medicine and Bioethics**

Volume 46, Issue 6 December 2025

<https://link.springer.com/journal/11017/volumes-and-issues/46-6>

[Reviewed earlier]

## **Travel Medicine and Infectious Diseases**

Volume 68 November–December 2025

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/68/suppl/C>

[Reviewed earlier]

## **Tropical Medicine & International Health**

Volume 31, Issue 1 Pages: 1-111 January 2026

<https://onlinelibrary.wiley.com/toc/13653156/current>

[New issue; No digest content identified]

## **Vaccine**

Volume 72 6 February 2026

<https://www.sciencedirect.com/journal/vaccine/vol/72/suppl/C>

*Short communication Abstract only*

### **[Vaccine hesitancy among midlife and older adults in the United States](#)**

Paul L. Reiter, Mira L. Katz

Article 128054

*Review article Open access*

### **[The use of storytelling in COVID-19 vaccine promotion: A scoping review of interventions and campaigns](#)**

Suha Ballout, Sabreen A. Darwish, Patricia J. Kelly, Teresa Keller, ... Basil H. Aboul-Enein

Article 128098

*Review article Open access*

### **[Determinants of human papillomavirus vaccination decision-making in Japan: a scoping review exploring contextual, social, and adolescent-specific influences](#)**

Hana Tomoi, Sharon J.B. Hanley, Heidi J. Larson, Hiroaki Tomoi, Ken Masuda

Article 128111

*Review article Open access*

## **Closing the immunization gap: Overcoming barriers for new vaccine introduction in Southeast and South Asia**

Xinyu Zhang, Shu Chen, Shenglan Tang  
Article 128119

*Research article Abstract only*

## **COVID-19 vaccine production and the technological gap in the Global South: The cases of Argentina and Brazil**

Maria J. Haro Sly, Lautaro Zubeldia  
Article 128141

### **Vaccines**

<https://www.mdpi.com/journal/vaccines>  
[Accessed 01 Feb 2026]  
*Open Access Article*

#### **Timeliness of Routine Vaccination, Catch-Up Completion, and Immune Function in Chinese Children with Special Healthcare Needs: A Retrospective Cohort Study**

by Yuyuan Zeng, Xihan Li, Yu Tian, Yuming Liu, Jianhong Wang, Qi An, Chuanyu Yang, Bo Zhou, Lili Zhang, Yangmu Huang and Lin Wang

Vaccines 2026, 14(2), 149; <https://doi.org/10.3390/vaccines14020149> (registering DOI) - 31 Jan 2026  
*Abstract*

Background: Children with special healthcare needs (CSHCNs) face persistent barriers to timely immunization in China, but comparative evidence across disease groups and vaccines, and data on immune function, are limited. Methods: We conducted a retrospective cohort study linking electronic medical records, vaccination records, [\[...\]](#)

*Open Access Article*

#### **Health Worker Influenza Vaccination Programs: A Key to Pandemic Preparedness and Effective COVID-19 Vaccine Deployment in Low- and Middle-Income Countries**

by Margaret McCarron, Chelsey Griffin, Tat S Yau, Julie Garon Carlton, Jaymin C Patel, Claire B Hugo, Carsten Mantel, Lindsay B. Saber, Shoshanna Goldin, Ann Moen, Kathryn E Lafond, Jenny A Walldorf, Terri Hyde and Joseph Sewell Bresee

Vaccines 2026, 14(2), 130; <https://doi.org/10.3390/vaccines14020130> - 28 Jan 2026

*Abstract*

Background/Objectives: The COVID-19 pandemic presented an urgent global need to quickly vaccinate health workers (HWs). We used this unique circumstance to assess whether mature influenza vaccination programs for HWs facilitated rapid deployment of COVID-19 vaccines in low- and middle-income countries (LMICs). Methods:

### **Value in Health**

February 2026 Volume 29 Issue 2 p175-346  
<https://www.valueinhealthjournal.com/current>

*Systematic Literature Review*

#### **Mapping Methodologies for Economic Evaluation of Digital Health Technologies: A Scoping Review**

Ana Rita Santos, et al.  
Published online: September 24, 2025  
p311-323 Open Access

## World Medical Journal – Official Journal of The World Medical Association

Nr. 4, December 2025, vol. 71

<https://www.wma.net/publications/world-medical-journal/>

[Reviewed earlier]

## World Development

Volume 200 April 2026

<https://www.sciencedirect.com/journal/world-development/vol/200/suppl/C>

[Reviewed earlier]

::::::

::::::

### ***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

::::::

::::::

## ***Pre-Print Servers***

### **arXiv**

<https://arxiv.org/>

[Accessed 01 Feb 2026]

[*Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Computational Engineering, Finance, and Science; General Literature; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics*]

arXiv:2601.18622 [pdf, html, other]

### **[Brazilian Social Media Anti-vaccine Information Disorder Dataset -- Telegram \(2020-2025\)](#)**

João Phillippe Cardenuto, Ana Carolina Monari, Michelle Diniz Lopes, Leopoldo Lusquino Filho, Anderson Rocha

Over the past decade, Brazil has experienced a decline in vaccination coverage, reversing decades of public health progress achieved through the National Immunization Program (PNI). Growing evidence points to the widespread circulation of vaccine-related misinformation -- particularly on social media platforms -- as a key factor driving this decline. Among these platforms, Telegram remains the only major platform permitting accessible and ethical data collection, offering insight into public channels where vaccine misinformation circulates extensively. This data paper introduces a curated dataset of about four million Telegram posts collected from 119 prominent Brazilian anti-vaccine channels between 2020 and 2025. The dataset includes message content, metadata, associated media, and classification related to vaccine posts, enabling researchers to examine how false or misleading information spreads, evolves, and influences public sentiment. By providing this resource, our aim is to support the scientific and public health community in developing evidence-based strategies to counter misinformation, promote trust in vaccination, and engage compassionately with individuals and communities affected by false narratives. The dataset and documentation are openly available for non-commercial research, under strict ethical and privacy guidelines at [this https URL](https://gatesopenresearch.org/2026/01/01/brazilian-social-media-anti-vaccine-information-disorder-dataset--telegram-2020-2025/)

<https://gatesopenresearch.org/browse/articles>

[Accessed 01 Feb 2026]

[*Filter: All articles*]

Research Article metrics

### **[Zero-Dose Childhood Immunization in Conflict-Affected PSNP Districts of Ethiopia: A Comparative Cross-Sectional Study](#)**

Fisseha Shiferie, Gashaw Andargie Bik, Kidist Negash, Dawit A Tsegaye, Gobena Seboka, Getnet Birhanu, Shibabaw Ewnetie, Tenaye Abate, Uche RalphOpara, Wondwossen A Alemayehu, Joseph Odu, Steven Neri, Frank DelPizzo, Kidist Belete

Funder

Gates Foundation

PUBLISHED 12 Jan 2026

The study highlights persistent inequities in immunisation coverage in conflict-affected settings. It also demonstrates comparability between intervention and comparison PSNP districts in zero-dose prevalence and its determinants. These baseline findings provide a foundation for attributing future post-intervention improvements to enhanced integration of health services within the PSNP framework.

[Launched in 2005, Ethiopia's Productive Safety Net Programme (PSNP) is the country's flagship social protection initiative, designed to address chronic food insecurity among vulnerable households through conditional or unconditional transfers of food or cash. In recent years, the programme has expanded to incorporate nutrition, health, and water, sanitation, and hygiene components...including immunisation (Abay et al., 2022; World Bank, 2020).Globally, there is increasing recognition of the potential for integrated service delivery and social protection systems to reach zero-dose children (UNICEF, 2023).]

### **medRxiv**

<https://www.medrxiv.org/content/early/recent>

[Accessed 01 Feb 2026]

[*Filter: All articles*]

### **[Wastewater-based epidemiology to enhance public health preparedness and response during large-scale events: experiences from the 2024 Republican and Democratic National Conventions – Milwaukee, WI and Chicago, IL](#)**

Peter MV DeJonge, Ian Pray, Rachel Poretsky, Martin Shafer, Sandra L McLellan, Alyse Kittner, Colin Korban, Dolores Sanchez Gonzalez, Adam Horton, Modou Lamin Jarju, Chi-Yu Lin, Erin P Newcomer, Hannah J Barbian, Stefan J Green, Bernardo Burbano-Abril, Nathan Kloczko, Megan Rasmussen, Dagmara Antkiewicz, Adélaïde Roguet, Devin Everett, Melissa K Schussman, Veronica McSorley, Peter Ruestow

medRxiv 2026.01.26.26343470; doi: <https://doi.org/10.64898/2026.01.26.26343470>

### **[Progress towards the End TB Goals in South Africa: A comparative cost-effectiveness analysis of tuberculosis interventions](#)**

Mmamapudi Kubjane, Lise Jamieson, Leigh F. Johnson, Kamban Hirasen, Lezanie Coetzee, Clive Ramushu, Denise Evans, Pren Naidoo, Gesine Meyer-Rath

medRxiv 2026.01.26.26344817; doi: <https://doi.org/10.64898/2026.01.26.26344817>

### **[Mathematical assessment of the impact of the R21/Matrix-M vaccine on the control of malaria in children in Burkina Faso](#)**

Arnaja Mitra, Abba B. Gumel

medRxiv 2026.01.25.26344791; doi: <https://doi.org/10.64898/2026.01.25.26344791>

### **[Democracy, Inequality and Covid-19 Pandemic Outcomes: Age-standardised excess mortality and GDP growth in island and non-island jurisdictions](#)**

Matt Boyd, Michael G Baker, Nick Wilson  
medRxiv 2026.01.22.26344652; doi: <https://doi.org/10.64898/2026.01.22.26344652>

## **OSF Pre-prints**

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>  
[Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]  
[No new digest content identified]

## **Wellcome Open Research**

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 01 Feb 2026]

Research ArticleOpen Access

[\*\*REVISED - Adoption and use of the 7-1-7 timeliness metrics for detection, notification, and early response actions to public health events: an observational study in Liberia, January 2024– June 2025\*\*](#)

[version 2; peer review: 2 not approved]

Ralph W. Jetoh, et al.

In July 2021, a new global target of 7-1-7 was proposed to improve early detection, notification and rapid control of public health threats. Liberia adopted 7-1-7 metrics in September 2023, with the framework embedded in the health and data monitoring systems by January 2024. The study aimed to document factors that influenced 7-1-7 adoption and assess how well the health systems performed for 7-1-7 metrics between January 2024 and June 2025.

Research Article Open Access

[\*\*Evaluating the 7-1-7 Outbreak Response Metric: Modelling and Implementation Insights for Ebola, Measles, and Anthrax in Central and Eastern Uganda, 2025\*\*](#)

[version 1; peer review: awaiting peer review]

Abel W. Walekhwa, et al.

Uganda's recent progress in public health emergency preparedness, as reflected in the 2023 Joint External Evaluation, underscores the relevance of the 7-1-7 framework. Although the WHO recommends detecting outbreaks within 7 days, notifying within 1 day, and responding within 7 days, evidence on the incremental benefits of meeting these targets remains limited, particularly in resource-constrained settings. This study modelled the number of cases averted and the cost-effectiveness of achieving 7-1-7 timelines for Ebola, anthrax, and measles in Uganda.

\* \* \* \*

## **Think Tanks**

**Brookings** [to 01 Feb 2026]

<http://www.brookings.edu/>

Research, Events

No new digest content identified.

**Center for Global Development** [01 Feb 2026]

<https://www.cgdev.org/>

All Research

*No new digest content identified.*

**Chatham House** [to 01 Feb 2026]

<https://www.chathamhouse.org/>

*Selected Analysis, Comment, Events*

*No new digest content identified.*

**Council on Foreign Relations** [01 Feb 2026]

<https://www.cfr.org/media/news-releases>

*New Releases [Selected]*

*No new digest content identified.*

**CSIS** [to 01 Feb 2026]

<https://www.csis.org/>

*Reports [Selected]*

**[Lost in Definition: How Confusion over Agentic AI Risks Governance](#)**

Confusion over what “agentic AI” actually means is creating governance gaps that risk flawed procurement, unclear accountability, and dangerous mismatches between autonomy and human judgment.

Brief by Yasir Atalan, Ian Reynolds, and Benjamin Jensen — January 26, 2026

**McKinsey Global Institute** [to 01 Feb 2026]

<https://www.mckinsey.com/mgi/overview>

*Featured Research*

*No new digest content identified.*

**ODI** [Overseas Development Institute] [to 01 Feb 2026]

<https://odi.org/en/publications/>

*Publications [Selected]*

*No new digest content identified.*

**Pew Research Center** [to 01 Feb 2026]

<https://www.pewresearch.org/>

*Latest Publications*

*No new digest content identified.*

**Rand** [to 01 Feb 2026]

<https://www.rand.org/pubs.html>

*Published Research [Selected]*

Jan 26, 2026

**[Living Framework and Guidelines for Information Disclosure in Biosecurity: A Biosecurity Research Oversight Framework and Toolkit](#)**

Information hazards are risks from the dissemination or the potential dissemination of true information that may cause harm. This living framework and toolkit support responsible decisions about oversight of biosecurity information hazards.

**Urban Institute** [to 01 Feb 2026]

<https://www.urban.org/research>

*New Research Publications - Selected  
Research Report*

**Shared and Mutual Ownership for the Common Good**

*A Compendium of Models*

Rebecca Marx, Brett Theodos

January 26, 2026

This review of shared and mutual ownership models expands the understanding of shared ownership mechanisms in the US economy. It is a guide for those navigating the long-standing and growing shared ownership field.

Shared ownership can take many forms, informed by geographic, cultural, or sector-related contexts. It shows up in numerous sectors (e.g., land, commercial real estate, housing, small businesses, utilities, financial institutions, and data) and involves multiple types of owners (e.g., residents, workers, and consumers or producers of products). Shared ownership models have originated and grown in rural and urban settings and in politically conservative and progressive ones.

**World Economic Forum** [to 01 Feb 2026]

<https://agenda.weforum.org/press/>

*Media [Selected]*

*No new digest content identified.*

:::::

:::::

***Public Consultations/Call for Inputs/Call for Papers***

**Request for Information on Draft NIH Controlled-Access Data Policy and Proposed Revisions to NIH Genomic Data**

NATIONAL INSTITUTES OF HEALTH (NIH) Notice Number: NOT-OD-26-023 **Response Date:**  
**March 18, 2026**

*Purpose*

The National Institutes of Health (NIH) is requesting public input on its proposal to establish harmonized and transparent policy requirements for protecting human participant research data. Specifically, NIH proposes (1) establishing policy requirements for which data should be controlled-access under NIH data sharing policies, and (2) revising the NIH Genomic Data Sharing Policy to simplify and harmonize requirements.

*Background*

NIH serves as the steward of a wide range of research data and continuously works to optimize open sharing with appropriate protections throughout the entire data lifecycle. Given its numerous established data policies, NIH is proposing a holistic update to its data policy framework to strengthen data protections, clarify requirements, and reduce duplicative burden.

NIH is proposing a new NIH Controlled-Access Data Policy to support the research community in fulfilling NIH data sharing expectations. This proposed policy specifies human participant data types required to be managed via controlled-access and provides criteria for assessing the need for controls for other data types. It also provides a standard set of expectations across NIH Institutes, Centers and Offices to promote maximal responsible human participant data sharing through controlled access while simultaneously responding to emergent privacy and security risks, including those outlined in the following security directives...

## **Working Group XV – Pharmacoepidemiology for Public Health - PUBLIC CONSULTATION**

### **DRAFT REPORT**

Pharmacoepidemiology aims to appraise and understand the use and effects — both beneficial and adverse — of medicines in real-world settings. As such it can be considered a bridge science, linking clinical pharmacology, epidemiology, public health and the social sciences.

Medicines are public health tools. With regard to the quality and transparency of the assessment of their effectiveness and safety, they are increasingly subject to the expectations and requirements of patients, healthcare professionals and regulators. Those involved in the development and delivery of medicines must therefore take full account of the aforementioned paradigm shifts. Additionally, the arrival of novel therapeutic agents, such as gene therapy, biologics and mRNA vaccines, whose modes of action and interactions with living organisms have very little in common with those of the more traditional chemical medicines, has brought into question the classic elements of pharmacovigilance and pharmacoepidemiology, such as the dose–effect relationship, drug causation criteria and the determination of drug exposure.

CIOMS full [concept note on Pharmacoepidemiology for Public Health](#)

You are invited to review and comment on the draft report entitled *Realising the Potential of Pharmacoepidemiology for Public Health Decision-Making*. [Download the report here.](#)

Please note that comments will only be considered when using the [template provided here](#). The **deadline to submit your comments is 13 March 2026**.

\* \* \* \*

#### ***Contents [click to move among sections]***

[:: Milestones, Perspectives](#)  
[:: WHO](#)  
[:: Organization Announcements](#)  
[:: Journal Watch](#)  
[:: Pre-Print Servers](#)

\* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

::::::

*Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

:::::::

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#) and industry resource members Janssen/J&J, Pfizer, Sanofi US, and GSK. (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

\* \* \* \*